使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning. My name is Lisa and I will be your conference operator today. At this time, I would like to welcome everyone to the Valeant second-quarter 2016 results conference call.
各位早安。我叫 Lisa,今天將擔任本次電話會議的接線員。此刻,我謹代表公司歡迎各位參加 Valeant 2016 年第二季業績電話會議。
(Operator Instructions)
(接線員指示)
Thank you. Ms. Laurie Little, you may begin your conference.
謝謝。Laurie Little 女士,您可以開始您的會議。
- IR
- IR
Thank you, Lisa. Good morning, everyone, and welcome to Valeant's Investor Relations' conference call, where we will be discussing our second-quarter 2016 financial results. Participating on today's call are: Joe Papa, Chief Executive Officer; Rob Rosiello, Chief Financial Officer; Dr. Ari Kellen, Company Group Chairman; Anne Whitaker, Company Group Chairman; and Linda LaGorga, our Treasurer.
謝謝你,Lisa。各位早安,歡迎參加 Valeant 投資人關係電話會議,我們將在此討論 2016 年第二季財務結果。今天參與會議的有:執行長 Joe Papa;財務長 Rob Rosiello;公司集團主席 Ari Kellen 博士;公司集團主席 Anne Whitaker;以及財務主管(Treasurer)Linda LaGorga。
In addition to a live webcast, a copy of today's slide presentation can be found on our website under the Investor Relations section. Before we begin, our presentation today contains forward-looking information. We would ask that you take a moment to read the forward-looking statement legend at the beginning of our presentation, as it contains important information.
除現場網路直播外,今日簡報投影片亦可於本公司網站「投資人關係」專區取得。在開始之前,提醒各位:我們今天的簡報包含前瞻性資訊。我們請各位花一點時間閱讀簡報開頭的前瞻性聲明說明,當中包含重要資訊。
In addition, this presentation contains non-GAAP financial measures. For more information about these measures, please refer to slide 2. Non-GAAP reconciliations can be found in the appendix to the presentation posted earlier today and posted on our website.
此外,本簡報包含非 GAAP 財務衡量指標。關於這些指標的更多資訊,請參閱投影片第 2 頁。非 GAAP 調節表可於今日稍早發布並上傳至本公司網站之簡報附錄中查閱。
Finally, the financial guidance in this presentation is effective only as of today. It is our policy to update or affirm guidance only through broadly disseminated public disclosure. With that, I will turn the call over to Joe.
最後,本簡報中的財務指引僅於今日有效。本公司政策為僅透過廣泛公開揭露的方式更新或重申指引。接下來,我把電話交給 Joe。
- CEO
- CEO
Thank you, Laurie. Good morning, everyone, and thank you for joining us. Today we would like to cover the following topics. First, we are reaffirming our 2016 full-year guidance. Next, Rob will cover second-quarter 2016 financial results. I will then cover the progress we have made since the quarter one call in June. Then lastly, we will unveil our plans for the new Valeant.
謝謝你,Laurie。各位早安,感謝各位加入我們。今天我們想涵蓋以下主題。首先,我們重申 2016 年全年指引。接著,Rob 將說明 2016 年第二季財務結果。然後我會說明自 6 月第一季電話會議以來我們所取得的進展。最後,我們將揭示「新 Valeant」的計畫。
To begin, on slide 5, we are reaffirming our 2016 full-year guidance of total revenue of $9.9 billion to $10.1 billion and adjusted non-GAAP EPS of $6.60 to $7. We continue to expect an adjusted EBITDA number from $4.8 billion to $4.95 billion for 2016. We've made significant progress in the last 60 days in identifying our challenges and have begun executing on our plans to accelerate growth and profitability in the second half of 2016. We will talk more about this later.
首先,在投影片第 5 頁,我們重申 2016 年全年指引:總營收 99 億至 101 億美元,調整後非 GAAP 每股盈餘(EPS)6.60 至 7.00 美元。我們仍預期 2016 年調整後 EBITDA 為 48 億至 49.5 億美元。在過去 60 天,我們在辨識挑戰方面取得重大進展,並已開始執行計畫,以加速 2016 年下半年成長與獲利。我們稍後會再詳細說明。
I would like to turn the call over now to Rob to review the second-quarter 2016 financial results.
現在我想把電話交給 Rob,請他回顧 2016 年第二季財務結果。
- CFO
- CFO
Thank you, Joe. Before I begin, I want to point out that our GAAP and non-GAAP financial summaries can be found in the appendix of this presentation and in our press release issued earlier today. For the second quarter of 2016, our total revenue was $2.42 billion, an improvement from the first quarter of 2016. When combined with the first quarter, this represents approximately 48% of the midpoint of 2016 full-year guidance.
謝謝你,Joe。在開始之前,我想指出,我們的 GAAP 與非 GAAP 財務摘要可在本簡報附錄以及今日稍早發布的新聞稿中找到。2016 年第二季,我們總營收為 24.2 億美元,較 2016 年第一季有所改善。若與第一季合併計算,約相當於 2016 年全年指引中點的 48%。
Adjusted COGS was $630 million in Q2, or 26% of sales. This was slightly higher than the first quarter due to unfavorable product mix. Adjusted SG&A spend of $662 million improved on a sequential basis, and represented 27% of revenue for the quarter.
第二季調整後銷貨成本(COGS)為 6.30 億美元,占銷售額 26%。由於產品組合不利,該比率較第一季略高。調整後銷售、一般及行政費用(SG&A)為 6.62 億美元,較前一季改善,且占本季營收 27%。
In Q2, adjusted SG&A excluded $10.2 million in legal and other professional fees associated with legal and governmental proceedings or investigations related to our distribution, pricing, and related matters, including our former relationship with Philidor. As a comparison, in Q1, this number was $29 million. We do not add back legal expenditures for ordinary course of business, but these represent extraordinary costs.
第二季的調整後 SG&A 排除了 1,020 萬美元的法律及其他專業費用,該等費用與我們在通路、定價及相關事項(包括先前與 Philidor 的關係)所涉之法律與政府程序或調查相關。相較之下,第一季該金額為 2,900 萬美元。我們不會將日常營運的一般法律支出加回,但上述屬於非常態成本。
Our non-GAAP operating margin improved from 39% in the first quarter of 2016 to 42% in the second quarter. GAAP EPS was a loss of $0.88 and adjusted non-GAAP EPS was $1.40, which when combined with the first-quarter results, accounted for approximately 39% of the midpoint of our first full-year 2016 guidance.
我們的非 GAAP 營業利益率由 2016 年第一季的 39% 提升至第二季的 42%。GAAP 每股盈餘為虧損 0.88 美元,調整後非 GAAP 每股盈餘為 1.40 美元;若與第一季結果合併,約占我們 2016 年全年第一版指引中點的 39%。
As we stated on the Q1 call, we expected a 40%/60% earnings split between first-half and second-half 2016. Cash flow from operations was $448 million. Q2 adjusted EBITDA was $1.09 billion, which when combined with Q1 of $1.01 billion, accounted for approximately 43% of the midpoint of 2016 guidance.
如同我們在第一季電話會議所述,我們預期 2016 年上、下半年獲利分布為 40%/60%。營運活動現金流為 4.48 億美元。第二季調整後 EBITDA 為 10.9 億美元,與第一季的 10.1 億美元合計後,約占 2016 年指引中點的 43%。
On slide 7, we compare our Q2 2016 financial results to current consensus. We believe the variance is attributable to slower recovery in dermatology and increased investment in R&D. Revenue was impacted by our dermatology business, where we have made good progress and continue to work with our partners on further enhancements.
在投影片第 7 頁,我們將 2016 年第二季財務結果與目前市場共識進行比較。我們認為差異主要來自皮膚科業務復甦較慢,以及研發(R&D)投資增加。營收受到皮膚科業務影響;我們已取得良好進展,並持續與合作夥伴就進一步改善進行合作。
Our gross margin was down by $69 million due to the same factors that impacted revenue, as well as out-performance in emerging markets, which carry lower gross margin to the overall mix. As mentioned previously, our non-GAAP SG&A spend came down sequentially to 20% of revenue, while non-GAAP R&D was $108 million, excluding a charge of $15.5 million in connection with a settlement to resolve certain disputed invoices related to transition services.
我們的毛利因影響營收的相同因素而減少 6,900 萬美元,此外,新興市場表現優於預期亦影響整體組合,因其毛利率較低。如前所述,我們的非 GAAP SG&A 支出較前一季下降至營收的 20%;同時,非 GAAP 研發費用為 1.08 億美元,並排除與和解以解決部分與轉換服務相關之爭議發票所產生的 1,550 萬美元費用。
Our R&D spend was higher than analysts' expectations due to the incremental investment associated with the [FD] panel for Broda, an expense we all agree was well worth it. Our effective tax rate of roughly 15% this quarter reflects our updated tax reporting, which we have spoken about in the past few quarters. But to be clear, actual cash outlays for taxes remain below a 5% rate. Finally, the bottom line reflects results reflect increased R&D investment and a slower recovery in the higher margin dermatology business, which Joe will discuss in more detail shortly.
我們的研發支出高於分析師預期,原因是與 Broda 的 [FD] panel 相關的額外投資;我們一致認為這筆費用非常值得。本季約 15% 的有效稅率反映我們更新後的稅務申報方式,過去幾季我們已談及此事。但需要說明的是,實際稅金現金支出仍低於 5% 的稅率。最後,獲利表現反映研發投資增加,以及高毛利的皮膚科業務復甦較慢;Joe 稍後將更詳細說明。
We increased our investment in R&D, as we believe we can earn attractive returns on this incremental capital. Our R&D spend was $108 million in the quarter, a record number for Valeant. We plan to offset this increased investment through rebasing our cost structure and reducing our SG&A spend.
我們提高了研發投資,因為我們相信這些增量資本可帶來具吸引力的報酬。本季研發支出為 1.08 億美元,創 Valeant 歷史新高。我們計畫透過重設成本結構並降低 SG&A 支出,來抵銷這項增加的投資。
Although Valeant had been run on a decentralized model, we have found duplicative costs that can be eliminated, vendor rationalization that can be realized, and other efficiencies that will increase the profitability of the Company. We continue to be expect that SG&A will continue to decrease throughout the latter half of 2016 through these cost reduction initiatives.
儘管 Valeant 過去採分散式管理模式,我們已發現可被消除的重複成本、可實現的供應商整併(vendor rationalization),以及其他可提升公司獲利能力的效率。我們仍預期透過這些成本削減措施,2016 年下半年 SG&A 將持續下降。
As we move into the back half of 2016, slide 9 shows what drives the ramp to the midpoint of our guidance: $1.27 for Q1 plus a $1.40 for Q2 totals $2.67 for the first half of 2016. Using Q2's run rate performance for Q3 and Q4 would add $2.80. Tailwinds for the second half include: historical positive seasonality in Q3 and Q4; dermatology growth; Salix acceleration; the launch of oral Relistor; and growth in emerging markets, which will add roughly $1.15.
進入 2016 年下半年後,投影片第 9 頁顯示推動我們達到指引中點的因素:第一季每股盈餘 1.27 美元,加上第二季 1.40 美元,上半年合計為 2.67 美元。若以第二季的執行率(run rate)推估第三、第四季,將再增加 2.80 美元。下半年的利多包括:第三、第四季歷史上的正向季節性;皮膚科成長;Salix 加速;口服 Relistor 上市;以及新興市場成長,合計約可增加 1.15 美元。
Headwinds we are expecting include generic erosion, e.g. Ziana and Zegerid, an increased effective tax rate, which would remove roughly $0.20. Planned efficiencies in COGS, SG&A rationalization, and R&D timing, given the front-loaded first-half R&D investments and regulatory efforts, would account for roughly $0.38.
我們預期的利空包括:學名藥侵蝕(例如 Ziana 與 Zegerid),以及有效稅率上升,約將減少 0.20 美元。銷貨成本(COGS)規劃中的效率提升、SG&A 精簡,以及研發費用時點(考量上半年研發投資與法規作業較為前置),合計約可貢獻 0.38 美元。
With that, I will turn the call back to Joe.
接下來,我把電話交回給 Joe。
- CEO
- CEO
Thank you, Rob. We have been actively addressing the identified challenges in our dermatology portfolio and have made significant progress on these issues since our last call. Most importantly, we have restored net profitability to new dermatology prescriptions starting on August 5. This will improve the overall derm-selling price.
謝謝你,Rob。我們一直積極處理皮膚科產品組合中已辨識的挑戰,自上次電話會議以來在這些議題上已取得重大進展。最重要的是,我們自 8 月 5 日起已恢復皮膚科新處方的淨獲利能力。這將改善整體皮膚科的銷售價格。
We launched a new prior-authorization process with our partner on August 4, which should improve the adjudication experience. On June 27, we rolled out our program for independent pharmacies, which has been positively impact our prescription volumes. Enhance training and education for pharmacists is also expected to contribute to the improvement in volumes and profitability.
我們於 8 月 4 日與合作夥伴推出新的事前授權(prior-authorization)流程,應可改善理賠審核(adjudication)體驗。6 月 27 日,我們推出針對獨立藥局的方案,已對處方量帶來正面影響。加強對藥師的訓練與教育亦預期將有助於提升處方量與獲利能力。
We've also been reaching out to the physician community to restore their trust in Valeant's commitment to dermatology and have hosted meetings with more than 50 key opinion leaders and prescribers to listen to their feedback. I will speak more about Brodalumab later, but have said on numerous occasions that the pipeline is the new key to the Valeant.
我們也一直與醫師社群接觸,以重建他們對 Valeant 致力於皮膚科領域的信任,並已與超過 50 位關鍵意見領袖與處方醫師舉辦會議,聆聽他們的回饋。我稍後會再談 Brodalumab,但我已多次表示,研發管線是 Valeant 的新關鍵。
We're very pleased with the successful outcome of the Brodalumab FDA panel on July 19 and look forward to progressing with this important drug through the approval process. Finally, we continue to improve our managed-care position and are happy to see that we maintained key product access on the ESI and Caremark exclusion list.
我們對 7 月 19 日 Brodalumab 的 FDA 諮詢委員會取得成功結果感到非常滿意,並期待推進這項重要藥物的核准流程。最後,我們持續改善我們在管理式醫療(managed care)方面的地位,也很高興看到我們在 ESI 與 Caremark 的排除清單上仍維持了關鍵產品的可及性。
We have made significant progress in accelerating the growth of Salix portfolio. On slide 11, you see that Xifaxan monthly [TRX]s grew 28% year over year and we see an increase in the refill rate for the hepatic encephalopathy indication. The chart on slide 11 shows the current script trends as compared to past years.
我們在加速 Salix 產品組合成長方面已取得顯著進展。在投影片 11 上,您可以看到 Xifaxan 每月 [TRX](總處方量)年增 28%,且我們看到肝性腦病變適應症的續配率有所提升。投影片 11 的圖表顯示目前的處方趨勢與過去年度的比較。
Our new GM, Mark McKenna, and his team, have done a great job engaging with our sales force and we've seen a reduction in the sales force turnover rate through June, which is important to the success of this portfolio.
我們的新任總經理 Mark McKenna 與其團隊在與我們的銷售團隊互動方面做得非常出色;截至 6 月,我們已看到銷售團隊離職率下降,這對該產品組合的成功至關重要。
In addition to Xifaxan, we have seen strong growth in other products in the GI franchise, with three key products, Uceris, Relistor, and Apriso, all growing in the mid-to-high single-digit range. Finally, the recent approval of Relistor Oral provides us with the opportunity to sustain long-term growth in this product and we're working towards a September 2016 launch.
除了 Xifaxan 之外,我們也看到腸胃(GI)事業群的其他產品強勁成長;三項關鍵產品 Uceris、Relistor 與 Apriso 均以中至高個位數的幅度成長。最後,Relistor 口服劑型近期獲准,為我們提供了維持該產品長期成長的機會,我們正朝 2016 年 9 月上市的目標推進。
We remain committed to pay down at least $1.7 billion of permanent debt in 2016, as we illustrate on slide 12. Our cash position at quarter end was approximately $850 million and we have repaid $1.29 billion of permanent debt year to date. That includes approximately $880 million in debt reductions since the end of the first quarter.
我們仍致力於在 2016 年至少償還 17 億美元的永久性債務,如投影片 12 所示。季度末我們的現金部位約為 8.5 億美元,年初至今已償還 12.9 億美元的永久性債務。其中包括自第一季末以來約 8.8 億美元的債務減少。
We have now completed all 2016 scheduled amortization payments, as well as the first quarter of 2017 amortization payment. Looking forward to 2017, we have only approximately $475 million in remaining mandatory term-loan amortization.
我們現在已完成 2016 年所有排定的攤還付款,以及 2017 年第一季的攤還付款。展望 2017 年,我們僅剩約 4.75 億美元的強制性定期貸款攤還。
On slide 13, we have made progress with the business since our call in June. On the commercial front, we have now launched a prior-authorization program on August 4 with CoverMyMeds for the dermatology products, which should improve the adjudication process for our Walgreens portfolio. We have stabilized our sales team and importantly relaunched Ofloxacin Otic.
在投影片 13 上,自我們 6 月的電話會議以來,業務已取得進展。在商業面,我們已於 8 月 4 日與 CoverMyMeds 針對皮膚科產品推出事前授權(prior-authorization)計畫,這應可改善我們 Walgreens 產品組合的理賠審核流程。我們已穩定銷售團隊,並且重要的是重新上市 Ofloxacin Otic。
On the R&D front, we have recently partnered with the Wilson's Disease Association and will be funding research efforts with them. In addition, we have initiated new formulation activities for Xifaxan and licensed a novel bowel cleansing product that expect to file with the FDA in 2016.
在研發(R&D)方面,我們近期與威爾森氏症協會(Wilson's Disease Association)建立合作夥伴關係,並將與其共同資助研究工作。此外,我們已啟動 Xifaxan 的新劑型開發活動,並授權引進一項新型腸道清潔產品,預計於 2016 年向 FDA 提交申請。
We also announced the approval of Relistor Oral and the positive FDA panel vote for Brodalumab. While the complete response letter for Latanoprostene Bunod creates a delay, we are working towards a solution within the next six months.
我們也宣布 Relistor 口服劑型獲准,以及 Brodalumab 在 FDA 諮詢委員會獲得正面投票。雖然 Latanoprostene Bunod 的完整回覆函(complete response letter)造成延遲,但我們正努力在未來六個月內提出解決方案。
Finally, as we work towards streamlining the business, we have sold or have entered into agreements to sell Brodalumab EU rights, Synergetics US OEM assets, and Ruconest for a combined upfront payment of $181 million, and additional milestones of up to $329 million for achieving specific approval and sales milestones. Ruconest is a specialty orphan drug product that was non-core to the enterprise and we received a fair price.
最後,為了精簡業務,我們已出售或已簽署協議出售 Brodalumab 的歐盟權利、Synergetics 的美國 OEM 資產,以及 Ruconest,合計取得 1.81 億美元的預付款,並可在達成特定核准與銷售里程碑後,額外取得最高 3.29 億美元的里程碑款。Ruconest 是一項專科孤兒藥產品,並非公司核心業務,我們也獲得了合理的價格。
Now I would like to turn to the future and the new Valeant. As you can see on slide 14, we're setting the Company on a new path with new strategic imperatives, changes to the Management Team and structure, and new business segments, and a new direction.
現在我想談談未來與全新的 Valeant。如投影片 14 所示,我們正透過新的策略要務、管理團隊與組織架構的調整、以及新的事業部門與新方向,讓公司走上新的道路。
Valeant will be embarking on a new vision and mission on slide 15. We want to be a trusted healthcare partner and to improve people's lives with our healthcare products. The foundation of this will be upheld by five pillars that represent our core values. If we adhere to these core values, I believe that Valeant will be successful.
Valeant 將在投影片 15 上展開新的願景與使命。我們希望成為值得信賴的醫療保健夥伴,並透過我們的醫療保健產品改善人們的生活。其基礎將由五大支柱支撐,代表我們的核心價值。若我們遵循這些核心價值,我相信 Valeant 將會成功。
On slide 16, we will be focusing on five strategic imperatives as we move forward. They include: one, focusing on specialty-driven markets, where the relationship with physicians is critical. This will include core physician specialty areas such as dermatology, GI, and global eye care, where we believe we can make an important difference.
在投影片 16 上,隨著我們向前邁進,將聚焦五項策略要務。包括:第一,聚焦由專科驅動的市場,在這些市場中與醫師的關係至關重要。這將涵蓋皮膚科、腸胃科(GI)與全球眼科照護等核心醫師專科領域,我們相信在這些領域能帶來重要改變。
Also, we want to focus on markets with above average growth rates, where there is an unmet medical need and the aging population will ensure that market dynamics will be positive into the future. Three, we'd like to focus on building our leadership position and pipeline where we have a strategic advantage due to the breadth of our current product portfolio, and importantly, the investment we're making in R&D and our future new product pipeline.
此外,我們希望聚焦於成長率高於平均的市場,這些市場存在未被滿足的醫療需求,且人口老化將確保未來市場動態持續正向。第三,我們希望在具備策略優勢的領域建立領導地位與研發管線,這些優勢來自我們現有產品組合的廣度,以及更重要的,我們在研發上的投入與未來新產品研發管線。
We also want to drive efficient resource allocation where we invest in R&D productivity and appropriately streamline our cost structure. Finally, we will plan to build durable brands in key geographies across our global consumer, eye care, and branded generics across our emerging market footprint.
我們也希望推動更有效率的資源配置,投資於研發生產力,並適度精簡成本結構。最後,我們計畫在關鍵地理市場建立具持久性的品牌,涵蓋我們的全球消費者業務、眼科照護,以及在新興市場布局中的品牌學名藥。
Yesterday, we announced several new hires and internal promotions to align management to our new strategy. I want to welcome Christina, Scott, and Sam to the Company and thank the Management Team for taking on their respective new roles. We will continue to build and add to our team, but this is an important step in re-recruiting our top, top talent and aligning our leadership for the future. I want to also express my gratitude to Rob Chai-Onn, Laurie Little, and Dr. Pavel Mirovsky for all of their efforts over their many years at Valeant.
昨天,我們宣布了數項新聘任與內部晉升,以使管理團隊與我們的新策略一致。我想歡迎 Christina、Scott 與 Sam 加入公司,並感謝管理團隊承擔各自的新職務。我們將持續建立並擴充團隊,但這是重新招募我們最頂尖人才、並為未來調整領導團隊的重要一步。我也要對 Rob Chai-Onn、Laurie Little 與 Pavel Mirovsky 博士多年來在 Valeant 的付出表達感謝。
In the past, Valeant has been organized primarily by geography. We intend to structure the Company through three new segments as we note on slide 18. First, a Durable Growth segment representing approximately 50% of our revenue. This will encompass the Bausch & Lomb franchise, global consumer, and most of our international markets. Second, a Growth segment, representing approximately 30% of our revenue, will include our branded Rx products, where a majority of our future investments will occur.
過去,Valeant 主要依地理區域來組織。我們打算如投影片 18 所示,透過三個新的事業部門來架構公司。第一個是「持久成長」(Durable Growth)部門,約占我們營收的 50%。這將涵蓋 Bausch & Lomb 事業群、全球消費者業務,以及我們大多數的國際市場。第二個是「成長」(Growth)部門,約占我們營收的 30%,將包含我們的品牌處方藥(branded Rx)產品,未來大部分投資將在此發生。
Finally, our Cash Generating segment, representing approximately 20% of our revenue, will encompass those portfolios which we will look to optimize as a high-margin and low-investment business. This new structure will provide our investors with greater transparency into our business, with margin and profitability profiles. We plan to roll out this new segment structure in the third quarter.
最後,我們的「現金創造」(Cash Generating)部門,約占我們營收的 20%,將涵蓋那些我們將以高毛利、低投資的方式加以最佳化、以提升現金回收的產品組合。這個新架構將讓投資人更清楚了解我們的業務,包含毛利與獲利能力輪廓。我們計畫在第三季推出這個新的部門架構。
Now I'd like to turn the call over back to Rob.
現在我想把電話會議交回給 Rob。
- CFO
- CFO
On slide 19, our Durable Growth segment will include global eye care, global consumer, and our international markets. These are franchises with durable product characteristics. We expect 2017 and 2018 revenue growth in the range of 6% to 8% and EBITDA growth in the 8% to 12% range.
在投影片 19 上,我們的「持久成長」部門將包含全球眼科照護、全球消費者業務,以及我們的國際市場。這些都是具備持久產品特性的事業群。我們預期 2017 與 2018 年營收成長介於 6% 至 8%,EBITDA 成長介於 8% 至 12%。
We expect our R&D spend in this area will be between 3% and 6% as we invest in future growth. Finally, non-GAAP EBITDA margin is expected to be in the 32% to 36% range for this segment.
我們預期該領域的研發支出將介於 3% 至 6%,以投資未來成長。最後,該部門的非 GAAP EBITDA 利潤率預期介於 32% 至 36%。
Our Branded Rx portfolio represents our Growth franchises, specifically GI, dermatology, dendreon, dentistry, and Canada. We expect 2017 and 2018 revenue growth in the 5% to 10% range and EBITDA growth in the 7% to 10 % range. We expect our R&D spend in this area will be between 7% and 9%. The EBITDA margin profile for our Growth segment is expected to be in the 50% to 55% range.
我們的品牌處方藥(Branded Rx)產品組合代表我們的「成長」事業群,具體包括腸胃科(GI)、皮膚科、Dendreon、牙科以及加拿大。我們預期 2017 與 2018 年營收成長介於 5% 至 10%,EBITDA 成長介於 7% 至 10%。我們預期該領域的研發支出將介於 7% 至 9%。「成長」部門的 EBITDA 利潤率輪廓預期介於 50% 至 55%。
Our final segment represents portfolios that are declining assets, that will be optimized for cash return. This includes our neuro and other portfolio, generics, and several other smaller businesses. While growth rates in this segment reflect the impact of near-term LOEs, we expect the longer term growth rate to be more moderate. The segment is expected to have EBITDA margins in the 65% to 75% range.
我們最後一個部門代表的是正在下滑的資產組合,將以現金回收最佳化為目標。這包括我們的神經科及其他產品組合、學名藥,以及其他數個較小的業務。雖然該部門的成長率反映了短期專利到期(LOE)的影響,但我們預期長期成長率將較為溫和。該部門的 EBITDA 利潤率預期介於 65% 至 75%。
Now I would like to turn the call over to Joe.
現在我想把電話會議交給 Joe。
- CEO
- CEO
Slide 22 illustrates our growth path from our 2016 guidance to 2018 adjusted EBITDA. While we will provide specific 2017 guidance at another time, we want to illustrate the important drivers for 2016 to 2018. For example, we will face negative headwind from loss of exclusivity, but which will be more than offset by four factors: base business growth, derm and Salix growth, new product launches, and annualized cost efficiencies.
第 22 張投影片說明了我們從 2016 年指引到 2018 年調整後 EBITDA 的成長路徑。雖然我們將在其他時間提供具體的 2017 年指引,但我們希望說明 2016 年至 2018 年的重要驅動因素。例如,我們將面臨因獨家權到期所帶來的負面逆風,但這將被四項因素所抵銷且綽綽有餘:基礎業務成長、皮膚科與 Salix 的成長、新產品上市,以及年度化的成本效率提升。
As we work to stabilize Valeant, we have already seen the success from our R&D team with a unanimous FDA AdComm vote for Brodalumab on July 19. As you can see on slide number 23, the panel voted 18 to zero in favor of this approval. This was a drug that many did not believe would receive a favorable panel recommendation, but the facts supported the unanimous vote, and our R&D team did a great job in the preparation and presentation of the material.
在我們努力穩定 Valeant 的同時,我們已經看到研發團隊的成果:Brodalumab 於 7 月 19 日在 FDA 諮詢委員會(AdComm)獲得一致通過的投票。如第 23 張投影片所示,委員會以 18 比 0 投票支持核准。這是一款許多人原本不認為會獲得正面委員會建議的藥物,但事實支持一致通過的投票,而我們的研發團隊在資料準備與簡報呈現方面做得非常出色。
This drug showed statistical superiority versus Stelara, which Stelara had worldwide sales of over $2.7 billion in 2015. Brodalumab also demonstrated impressive clearance rates and has a rapid onset of action. We will be working with the FDA as they continue the review process towards the PDUFA date on November of 2016.
該藥物相較於 Stelara 顯示出統計上更優的效果,而 Stelara 在 2015 年的全球銷售額超過 27 億美元。Brodalumab 也展現了令人印象深刻的清除率,且起效迅速。我們將與 FDA 合作,隨著其持續審查流程,朝向 2016 年 11 月的 PDUFA 日期推進。
As with all R&D programs, approvals can sometimes be delayed and this occurred with Latanoprostene Bunod, when we received a complete response letter on July 21. The concerns mention the CRL pertain to the CGMP at our facility in Tampa, Florida, following a February 2016 FDA inspection.
如同所有研發計畫,核准有時可能延遲;Latanoprostene Bunod 就發生了這種情況,我們於 7 月 21 日收到完整回覆函(CRL)。CRL 所提及的疑慮與我們位於佛羅里達州坦帕(Tampa)廠房的現行優良製造規範(CGMP)相關,係源於 FDA 於 2016 年 2 月的稽查。
We've been working with the FDA to resolve the open issues and we hope to complete activities required for an FDA re-inspection within six months. Importantly, the CRL did not identify any efficacy or safety concerns for Latanoprostene Bunod. Additionally, I wanted to be clear that this inspection and the resulting observations have not disrupted any manufacturing or shipment from the Tampa site and we do not expect any recalls of existing products.
我們一直與 FDA 合作以解決未結事項,並希望在六個月內完成 FDA 重新稽查所需的活動。重要的是,CRL 並未指出 Latanoprostene Bunod 任何療效或安全性疑慮。此外,我也想澄清,這次稽查及其後續觀察結果並未影響坦帕廠的任何製造或出貨,我們也不預期會對既有產品進行任何召回。
Our cash flow remains strong, as you can see on slide 25, and we have committed to using the vast majority of our cash flow to pay down debt. We expect cash flow to increase in 2017 as our contingent and milestone payments are expected to decrease and business development payments, which occurred in 2016, will not occur in 2017.
我們的現金流仍然強勁,如第 25 張投影片所示;我們已承諾將絕大部分現金流用於償還債務。我們預期 2017 年現金流將增加,因為或有款項與里程碑付款預計會下降,而 2016 年發生的業務開發付款在 2017 年將不會再發生。
For example, the deferred purchase price for Sprout of $500 million does not recur in 2017. We also do not expect to have large milestone payments in 2017 for approvals and potential approvals, such as this year's payment to Progenex for Oral Relistor and the potential payment for Brodalumab later this year. We expect that free cash flow and proceeds from non-core asset sales will help us to reduce debt by more than $5 billion during the next 18 months.
例如,對 Sprout 的 5 億美元遞延購買價在 2017 年不會再發生。我們也不預期 2017 年會有與核准及潛在核准相關的大額里程碑付款,例如今年支付給 Progenex 的 Oral Relistor 付款,以及今年稍晚可能針對 Brodalumab 的付款。我們預期自由現金流以及非核心資產出售所得將協助我們在未來 18 個月內減少超過 50 億美元的債務。
Since I became CEO of Valeant, I haven't had a meeting with shareholders or analysts in which the topic of debt covenants is not raised. As you know from our guidance, while we will continue to be in compliance with our financial maintenance covenants under our bank debt through 2016, our cushion is not as large as I would like it to be.
自從我成為 Valeant 的執行長以來,我與股東或分析師的每一次會面,幾乎都會被問到債務契約條款(debt covenants)的議題。正如你們從我們的指引所知,雖然我們在 2016 年底前仍將符合銀行債務下的財務維持性契約(financial maintenance covenants),但我們的緩衝空間沒有我希望的那麼大。
I believe this is one of the most important reasons why our stock price trades significantly below its intrinsic value. As a result, we have decided to seek to modify our interest coverage financial maintenance covenant with our lenders and will be launching the amendment process shortly. As you may know, our bank debt has traded at well over the last few months and is currently at around $0.98 on the dollar.
我認為這是我們股價顯著低於其內在價值的最重要原因之一。因此,我們已決定向放款人尋求修改利息保障倍數的財務維持性契約,並將在近期啟動修訂流程。你們可能也知道,我們的銀行債務在過去幾個月的交易價格一直高於面值附近,目前約為每 1 美元面值 0.98 美元。
This reflects a substantial asset value coverage in the quality of our asset base in cash-generating capability. Once the amendment is complete, I am looking forward to spending more time talking about our products, improving patients' lives, our growth trajectory, and pipelines, and less about our bank debt.
這反映出我們資產基礎的品質以及其創造現金能力所提供的顯著資產價值覆蓋。一旦修訂完成,我期待能花更多時間談論我們的產品、改善病患生活、我們的成長軌跡與產品線(pipelines),而更少談論我們的銀行債務。
On slide 26, we're currently evaluating strategic alternatives for a number of our core and non-core businesses and geographies that represent revenue greater than $2 billion. Let me be clear, that is we are looking at alternatives for a number of non-core businesses and geographies that represent revenue greater than $2 billion.
在第 26 張投影片,我們目前正在評估若干核心與非核心業務及地理區域的策略性替代方案,這些項目合計代表超過 20 億美元的營收。我要說清楚:我們正在評估的是若干非核心業務與地理區域的替代方案,這些項目合計代表超過 20 億美元的營收。
These assets represent a transaction value of up to $8 billion based on a weighted average of 11 times EBITDA multiple. This excludes core assets. We have received indications of interest on these assets and we have engaged respective banks and advisors to assist us in exploring our options.
以加權平均 11 倍 EBITDA 倍數計算,這些資產的交易價值最高可達 80 億美元。此處不包含核心資產。我們已收到對這些資產的意向表示(indications of interest),並已聘請相關銀行與顧問協助我們探索各種選項。
We fully intend to make decisions regarding our asset base in the best long-term interest of our shareholders. We expect to simplify the business and reduce our debt through strategic measures and cash generation over the next 12 to 18 months.
我們完全打算以符合股東長期最佳利益的方式,對我們的資產組合做出決策。我們預期在未來 12 至 18 個月內,透過策略性措施與現金創造來簡化業務並降低債務。
In summary, on slide 27, we have began the process to stabilize, turn around, and transform Valeant, creating a new Valeant. We are well into the first phase, stabilization, and have begun to pay down debt, attract talent, re-recruit our employees, fix the dermatology business, grow the GI franchise, and now, we will be officially launching new segments in the third quarter.
總結而言,如第 27 張投影片所示,我們已開始穩定、扭轉並轉型 Valeant 的流程,打造一個全新的 Valeant。我們已深入第一階段「穩定」,並已開始償還債務、吸引人才、重新凝聚員工、修復皮膚科業務、擴大腸胃道(GI)事業群,而現在我們將在第三季正式推出新的事業分部。
2017 to 2018 will bring the turn-around phase, where we focus on our efforts on specialty-driven markets and those with above-average returns. We plan to focus on creating leadership positions in our core areas, with good products and a future pipeline. We will also concentrate on efficient resource allocation and strengthening our balance sheet and continue to pay down debt.
2017 年至 2018 年將進入「扭轉」階段,我們將把重點放在專科驅動的市場,以及那些具備高於平均報酬的領域。我們計畫在核心領域建立領導地位,擁有良好的產品與未來的產品線。我們也將專注於有效率的資源配置、強化資產負債表,並持續償還債務。
In 2018 and beyond, we will transform this Company by leading in our respective categories, launching new products, balancing our growth through organic and inorganic means. Valeant and [stakers] have gone through a lot over the past year and I'm confident that through our focused strategy, smart investment, and a solid execution, the future is bright.
在 2018 年及之後,我們將透過在各自類別中取得領先、推出新產品,並以有機與無機方式平衡成長,來轉型這家公司。Valeant 與 [stakers] 在過去一年經歷了許多,我有信心透過我們聚焦的策略、明智的投資與扎實的執行,未來將一片光明。
Operator, now let's open the call for questions.
接線員,現在讓我們開放提問。
Operator
Operator
(Operator Instructions)
(接線員指示)
David Risinger, Morgan Stanley.
David Risinger,摩根士丹利。
- Analyst
- Analyst
Thanks very much. Joe, thanks for all of the commentary and color.
非常感謝。Joe,謝謝你提供所有評論與補充說明。
My question relates to what is assumed in the second-half guidance, so this is for Rob. In your second-half guidance, do you have any list price increases assumed? And also is there launch spending that is reflected in second-half guidance? Or if you launch new drugs, would the SG&A costs go above your current guidance? Thank you.
我的問題與下半年指引中的假設有關,所以這題是問 Rob。在你們的下半年指引中,是否假設有任何標價(list price)上調?另外,下半年指引是否已反映上市推廣支出(launch spending)?或者如果你們推出新藥,SG&A 成本是否會高於你們目前的指引?謝謝。
- CEO
- CEO
Rob, why don't you address this; and probably best to take him to the slide on a path to adjusted EPS guidance, in terms of the beginning part of this question?
Rob,你來回應一下;就這個問題的前半段而言,可能最好帶他看一下關於調整後 EPS 指引路徑的那張投影片?
- CFO
- CFO
I'd say two things. Firstly, the SG&A -- we plan to meet the original guidance of 26%. We were at 31% last quarter, 27%, and we have done the calculation and have our plans to hit that number. In terms of pricing, there's both a reflection of the discount, as well as potential modest price increases that we might take for the rest of the year. And the launch costs are embedded in our budgets. What is driving this -- just to go through it -- is the tailwinds, which are about [half] derm and Salix, the new product launches, the emerging markets, which have continued to grow with 10% growth again this quarter, and the typical seasonality, which we've always had. But the efficiencies provide an important path, and again, they are in the context of duplication and other costs, which we think we can easily address.
我想說兩點。第一,SG&A——我們計畫達成原先 26% 的指引。我們上季是 31%,這季是 27%,我們已完成計算並制定計畫以達到該數字。就定價而言,既反映折扣,也包含我們在今年剩餘期間可能採取的溫和漲價。而上市成本已納入我們的預算。推動因素——我簡單說明——包括順風因素,約有 [一半] 來自皮膚科與 Salix、新產品上市、新興市場(本季再度成長 10%),以及我們一向存在的典型季節性。但效率提升提供了重要路徑;同樣地,這是在重複配置與其他成本的脈絡下,我們認為可以很容易加以處理。
- Analyst
- Analyst
Thank you.
謝謝。
- CEO
- CEO
We're sticking with our 26%, and as Rob said, we are going to finance the incremental expenses for any new product launch through that efficiencies column that Rob is referring to.
我們會維持 26%,而如 Rob 所說,我們將透過他所提到的效率提升那一欄,來支應任何新產品上市所增加的費用。
Operator
Operator
David Maris, Wells Fargo.
David Maris,富國銀行。
- Analyst
- Analyst
Good morning, Joe.
早安,Joe。
I want to raise three different issues and then see if you can reconcile them. Valeant had testified in a Senate hearing that it was going to do business differently, and at the same hearing, you were criticized by a Wilson's Disease patient and senators, giving Cuprimine's high -- 330% -- price increase. Yesterday, you had a press release mentioning you are donating $100,000 to the Wilson's Disease Association.
我想提出三個不同的議題,然後看看你是否能加以調和。Valeant 曾在參議院聽證會上作證表示將以不同方式經營;而在同一場聽證會上,你也因 Cuprimine 高達 330% 的漲價而受到一位威爾森氏症(Wilson's Disease)病患與參議員的批評。昨天你們發布新聞稿提到將向威爾森氏症協會捐贈 100,000 美元。
You quoted Mary Graper, who I spoke with last night, and what she said is, she thought that Valeant, what they did by raising price would be criminal and that the donation was just a drop in the bucket; and that if you wanted to make a real difference, you should lower the price. Separately, you also mentioned in a press release yesterday that you reintroduced an Otic product, but missing in that was that, according to Price Rx, you also raised the price of that product in July by 31%.
你引用了我昨晚與之通話的 Mary Graper 的話;她說,她認為 Valeant 透過漲價所做的事可能構成犯罪,而那筆捐款只是杯水車薪;如果你真的想帶來實質改變,就應該降價。另外,你也在昨天的新聞稿中提到你們重新推出了一款耳科(Otic)產品,但其中未提到的是,根據 Price Rx 的資料,你們也在 7 月將該產品價格上調了 31%。
Then third, Valeant confirmed that, during the last month or so, one of your very prominent Board members held a dinner where selected Valeant owners could hear a discussion about Valeant's plans, including -- and again, I heard it second-hand, I wasn't there -- something you raised for the first time, changing the debt covenants was mentioned.
第三,Valeant 證實,在過去一個月左右,你們一位非常知名的董事會成員舉辦了一場晚宴,讓特定的 Valeant 股東可以聽取關於 Valeant 計畫的討論,其中包括——而且我再次強調,我是二手聽來的,我不在現場——首次提到可能要修改債務契約條款(debt covenants)。
Based on these three things and your prior statement in the call that business is changing, you're ushering in a new period -- to me, it sounds like these are all symptoms of the same old Valeant. Maybe if you could address each of these, but also the bigger picture item of -- are things really changing? Or is it just new paint on the same old shed?
基於這三件事,以及你在電話會議中先前所說業務正在改變、你們正引領一個新時期——在我聽來,這些都像是同一個老 Valeant 的症狀。也許你可以逐一回應這些問題,但也請談談更大的面向——事情真的在改變嗎?還是只是舊棚子刷了新漆?
- CEO
- CEO
David, thank you for your questions and your three different comments. Let me try to address them one at a time. First and foremost, let me say that I am absolutely confident that we're making changes at Valeant today. First and foremost, I will illustrate what we've done with the Management team in terms of taking new roles, bringing on new people into the Company. We brought on a brand new Board of Directors for the Company. At this point, we are at 12 Board members, 10 of which are new individuals. So there's clearly a new direction with the Company, as mentioned by both the Management team, as well as what we're doing with our Board of Directors, and importantly, the programs that we will take.
David,謝謝你的提問以及三點不同的評論。我試著逐一回應。首先也是最重要的,我非常有信心我們今天正在 Valeant 推動改變。首先,我會用我們在管理團隊方面所做的事來說明:調整新職務、引進新的人才加入公司。我們也為公司引入了全新的董事會。目前我們有 12 位董事,其中 10 位是新加入的個人。因此,無論是管理團隊所提到的方向,或是我們在董事會層面所做的事,以及更重要的是我們將推動的各項計畫,都清楚顯示公司正走向新的方向。
You did point out one product that we reintroduced, Ofloxacin Otic, but I don't think I've heard you mention of the fact that, other than the product prices that occurred in January, I do not believe there's been really any pricing to note at all since the time period of early in the year. We've made that, by itself, is certainly one evidence of some of the changes that have happened with the Valeant organization.
你確實指出我們重新推出的一項產品 Ofloxacin Otic,但我想你沒有提到的是,除了 1 月發生的產品定價調整之外,我不認為自今年年初以來還有任何值得一提的定價變動。我們在這方面的作法,本身就是 Valeant 組織已發生一些改變的證據之一。
Number two, we've reached out to the Wilson Disease Association. We've realized that some of the pricing that was taken was a mistake and we acknowledge that mistake. We're working very closely to try to make a difference in patients' lives and that is exactly what we think our efforts with the Wilson Disease Association is meant to do. By working with the Wilson's Disease Association, we're working very closely with Mary and her team and organization, to make a difference in patients' lives. We will do it through investment and research and development. We will also do it through helping the patients with patient data, patient awareness information, patient ability to get even apps and be able to follow their disease more closely. We think that is an important message. We have characterized that very closely in our slides today, by really (inaudible) what we're doing to try to improve patients' lives.
第二,我們已與威爾森氏症協會(Wilson Disease Association)接洽。我們意識到先前採取的部分定價是一個錯誤,我們也承認這個錯誤。我們正非常密切合作,努力在病患生活中帶來改變,而這正是我們與威爾森氏症協會合作的目的。透過與威爾森氏症協會合作,我們正與 Mary 及其團隊與組織緊密合作,以改善病患的生活。我們將透過投資以及研發來做到這點;也會透過協助病患取得病患資料、提升病患認知資訊、讓病患能取得甚至是 App,並能更密切追蹤其疾病。我們認為這是一個重要訊息。我們今天在投影片中也非常清楚地描述了這點,透過真正(聽不清楚)我們正在做的事,來嘗試改善病患的生活。
Finally, I don't think I have anything to add to the comment about any of our Board members. I don't know the specifics so anything I would be saying would be just speculation and I don't want to add to that.
最後,關於任何董事會成員的評論,我想我沒有什麼可以補充的。我不了解具體細節,所以我說的任何話都只會是推測,而我不想對此再多加揣測。
Operator
Operator
Umer Raffat, ISI Evercore.
Umer Raffat,ISI Evercore。
- Analyst
- Analyst
Thanks for taking my question.
謝謝讓我提問。
Joe, can you help us through where exactly you stand with that $8 billion in divestitures as per your slide? If you do go through with that, coupled with the debt paydown that is planned, are you effectively paying off 80% to 90% of your term loans? Where would the covenants stand if you do deliver on this over the next 12 months, number one?
Joe,你能否協助我們釐清你們投影片中所提到的 80 億美元資產剝離(divestitures)目前到底進展到哪一步?如果你們確實推進這件事,再加上計畫中的償債(debt paydown),你們是否等於償還了 80% 到 90% 的定期貸款(term loans)?如果你們在未來 12 個月內達成這些目標,契約條款(covenants)會落在什麼狀態?這是第一個問題。
Second, is the EPS hit from these only $0.50, if I'm doing my math right on the EBITDA? Then finally, for Linda, perhaps -- Linda, the covenant, at least the way it stands right now, is implying $4.8 billion as the trailing 12-month EBITDA needed during Q3. Will that change if you make the amendment? And if you could give us any color on Xifaxan and why is it not going up? Thank you.
第二,若我依 EBITDA 來算,這些交易對 EPS 的衝擊只有 0.50 美元,對嗎?最後想請教 Linda——至少以目前的契約條款來看,意味著在第三季需要過去 12 個月(trailing 12-month)的 EBITDA 達到 48 億美元。若你們進行修訂(amendment),這個要求會改變嗎?另外,能否談談 Xifaxan,為什麼它沒有上升?謝謝。
- CEO
- CEO
I'm going to try to get all them (laughter). Let's try to start with where we are with our non-core asset sales, specifically happening in the covenants. I will start with that, and then Linda, you might want to pick up on anything that I miss on that.
我會試著把這些都回答到(笑聲)。我們先從非核心資產出售的進度開始,特別是與契約條款相關的部分。我先談這個,然後 Linda,如果我有遺漏的地方,你可以再補充。
First and foremost, as I said on the call, we're evaluating our strategic alternatives for a number of non-core businesses and geographies that represent revenue of greater than $2 billion. Based on what we've seen for comparable asset sales and/or some unsolicited indications of interest we've received, these assets represent a transaction value of up to $8 billion based on 11 times EBITDA. That's where I start with.
首先,如我在電話會議中所說,我們正在評估多項非核心業務與地理區域的策略替代方案(strategic alternatives),其合計營收超過 20 億美元。根據我們看到的可比資產出售案例,和/或我們收到的一些未經邀請的意向表示(unsolicited indications of interest),以 11 倍 EBITDA 計算,這些資產的交易價值最高可達 80 億美元。這是我說明的起點。
One of the things I want to say, though, that this excludes our core asset sales. What we've tried to do in thinking about the use of these proceeds is that, in addition to some of the EBITDA generation from our cash, we do believe that we can certainly pay down, as I said in the call, at least $5 billion over the next 18 months, and potentially could be higher, if we sell all $8 billion. I'm not trying to suggest on the call we are doing that. At this time, [what] we're doing -- we don't have a plan to sell them; we're exploring our strategic options with some bankers that we've asked to help us. So only looking at exploring strategic options at this time. That is probably the first part of the commentary.
不過我想補充一點:這不包含我們的核心資產出售。我們在思考這些資金用途時,除了我們現金所帶來的一些 EBITDA 產生能力之外,我們確實相信,如我在電話會議中所說,未來 18 個月內我們至少可以償還 50 億美元,若出售全部 80 億美元資產,償還金額可能更高。我並不是要在電話會議中暗示我們一定會這麼做。目前我們所做的是——我們沒有一個要把它們賣掉的計畫;我們正在與一些我們請來協助的投行一起探索策略選項。所以目前只是探索策略選項。這大概是評論的第一部分。
Linda, on the question, the second question Umer asked is, if we paid down up to $5 billion plus some additional -- or let's say, up to $8 billion, that would take approximately 2/3 of the bank debt reduction from approximately $12 billion down to $4 billion, if we paid down $8 billion, is that correct?
Linda,關於 Umer 的第二個問題,如果我們償還最多 50 億美元再加上一些額外——或者說最多到 80 億美元——那將使銀行債務(bank debt)約減少 2/3,從約 120 億美元降到 40 億美元;如果我們償還 80 億美元,是這樣沒錯吧?
- Treasurer
- Treasurer
That is correct.
沒錯。
- CEO
- CEO
On this second part of the question, really what you've done, Umer, I believe, is just take that 11 times EBITDA and try to determine the $0.50 of EPS? Is that correct, is what you're saying?
至於第二部分的問題,Umer,我理解你是用 11 倍 EBITDA 來推算 EPS 影響約 0.50 美元?你是這個意思,對嗎?
- Analyst
- Analyst
Right.
對。
- CEO
- CEO
I'm going to tell you that I don't want to do math while I am on the phone, but directionally, that seems correct. But I want to get back to everybody on that question and get that confirmed, as we go through the call. I will try to get that answer by the end of the call. I just hate to do math while I am on the phone for an earnings call.
我得說,我不想在電話上做數學計算,但就方向性而言,聽起來是對的。不過我想在我們繼續進行電話會議時,再回覆大家並確認這個數字。我會試著在電話會議結束前給出答案。我只是很不喜歡在財報電話會議上當場算數。
The last question was on Xifaxan. Remind me that one, one more time?
最後一個問題是關於 Xifaxan。再提醒我一次,那個問題是什麼?
- Analyst
- Analyst
Basically, I was wondering, why isn't it going up? I wanted to clarify something on your $8 billion, too, but I will let you answer Xifaxan first.
基本上,我想知道為什麼它沒有上升。我也想釐清你們 80 億美元那部分的一點,但我先讓你回答 Xifaxan。
- CEO
- CEO
First and foremost, let me be clear, Xifaxan is going up, in terms of the prescriptions. The prescriptions for Xifaxan were up 28%. It was up -- the sales were up 36%, but that's a harder comparison. We just talk about the 28% prescription difference for Xifaxan is probably the best way to look at it. As you can see on our charts, though, it's very important to look at what happened to Xifaxan a year ago, in 2014, 2015, as we think through that, because that certainly gives you the best trajectory of change in terms of looking at (multiple speakers). Page 10 is what I'm referring to it, looking at the retail TRx performance, you could see, 2014, 2015, and then the Xifaxan increased, we see year-to-date versus 2015 on the slide.
首先我想說清楚,Xifaxan 的確在上升,就處方量而言。Xifaxan 的處方量成長了 28%。它——銷售額成長了 36%,但那是比較難比的口徑。我們只談 Xifaxan 處方量 28% 的差異,可能是最好的觀察方式。不過如你在我們的圖表中所見,在我們思考這件事時,非常重要的是要看一年前 Xifaxan 在 2014、2015 年發生了什麼,因為那能讓你在觀察(多位講者)時,得到最佳的變化軌跡。我指的是第 10 頁,看看零售 TRx 表現,你可以看到 2014、2015,然後 Xifaxan 的增加;我們在投影片上也看到今年迄今相較 2015 的增幅。
- Analyst
- Analyst
Got it. Joe, if I may just clarify.
了解。Joe,如果可以的話,我想先釐清一下。
First, on the $8 billion you mentioned, how much of that is unsolicited bids versus you guys doing comps analysis? If you could just give us, broadly, 1/3 of it as unsolicited business or not, number one? Then on Xifaxan -- Q1 versus Q2, just wanted to understand, why is flat to down versus being up? That's all I was trying to ask?
首先,關於你提到的 80 億美元,其中有多少是主動找上門的(unsolicited)出價,多少是你們自己做同業比較(comps)分析得出的?如果可以的話,能否大致告訴我們,其中約 1/3 是否屬於主動找上門的業務,這是第一點。第二點關於 Xifaxan——第一季對比第二季,我想了解為什麼是持平到下滑,而不是上升?我想問的就這些。
- CEO
- CEO
I'm sorry. Got it.
抱歉。了解。
- CFO
- CFO
It's two things. It's an inventory burn that took place in the quarter, and slightly lower ASPs, although ASPs have now stabilized.
有兩個原因:本季發生了庫存消化(inventory burn),以及 ASP(平均銷售價格)略有下降,不過 ASP 現在已經趨於穩定。
- CEO
- CEO
On the question on the unsolicited, we're probably not going to give you exact numbers, but I will say it's over 1/3 of it has been unsolicited offers that have come in to us, over 1/3 of it has been unsolicited offers. I probably don't want to go into it much further than that.
關於主動找上門(unsolicited)的問題,我們大概不會給你精確數字,但我可以說,超過 1/3 是主動找上門的報價(unsolicited offers)送到我們這裡來的,超過 1/3 都是主動找上門的報價。我可能不想再深入談更多。
- Analyst
- Analyst
Thank you so much.
非常感謝。
Operator
Operator
David Amsellem, Piper Jaffray.
David Amsellem,Piper Jaffray。
- Analyst
- Analyst
Thanks. On Nitropress and Isuprel, can you remind us what is in the guidance in terms of generic competition? And more broadly, what are your thoughts on when we're going to see generic competition on both products? Then also just a follow-up on Xifaxan -- you alluded to ASP stabilizing. Can you talk about what you're seeing there, in terms of prior ops and actual scripts getting filled? Do you think that the early success of Viberzi has actually been a headwind for Xifaxan in playing a role in why the product has not been growing as much as you would like? Thanks.
謝謝。關於 Nitropress 和 Isuprel,你能提醒我們在指引(guidance)中,對學名藥競爭(generic competition)的假設是什麼嗎?更廣泛地說,你們認為我們何時會在這兩個產品上看到學名藥競爭?另外再追問 Xifaxan——你們提到 ASP 已經穩定。能否談談你們看到的情況,例如先前授權(prior auth)以及實際處方(scripts)被配藥完成的狀況?你們是否認為 Viberzi 早期的成功,實際上對 Xifaxan 形成了逆風,並在某種程度上解釋了為什麼該產品的成長不如你們預期?謝謝。
- CEO
- CEO
Let me start with the Nitropress and Isuprel. We are expecting generic competition, as you noted. We believe that generic competition will occur some time in the next 6 to 12 months for both of the products, starting with Nitropress and then later Isuprel would experience a generic competition. But as I said, we expect it within the next 6 to 12 months. That was part of what Rob tried to illustrate on the loss of exclusivity, as he looked at some of the things that he had and certainly some of the things I talked about on the slide that looked at 2017, 2018 slide.
我先從 Nitropress 和 Isuprel 談起。如你所說,我們預期會有學名藥競爭。我們認為兩個產品的學名藥競爭會在未來 6 到 12 個月內某個時間點出現,先是 Nitropress,之後 Isuprel 才會面臨學名藥競爭。但如我所說,我們預期會在未來 6 到 12 個月內發生。這也是 Rob 試圖在失去獨占性(loss of exclusivity)那部分所說明的內容之一,他檢視了他手上的一些項目,當然也包括我在那張看 2017、2018 的投影片上提到的一些事情。
On the question of Xifaxan, we are very pleased with our position on commercial access. We believe Xifaxan has covered lives of more than 98% covered lives for the first half of 2016, so we think that's an excellent position to be in. Importantly, I can tell you that we've gotten a couple of very important wins recently with Xifaxan that has reduced the amount of prior authorization process that had to occur with Xifaxan. So for those reasons, we think we're in a very good position with Xifaxan. Obviously, some cases we had a chance to remove one of the step therapy that occurred, but we think the opportunity is very good.
關於 Xifaxan 的問題,我們對商業給付可近性(commercial access)的地位非常滿意。我們認為在 2016 年上半年,Xifaxan 的涵蓋人數(covered lives)超過 98%,所以我們覺得這是非常好的位置。更重要的是,我可以告訴你,我們最近在 Xifaxan 上取得了幾個非常重要的勝利,降低了 Xifaxan 需要進行的事前授權(prior authorization)流程。因此,基於這些原因,我們認為 Xifaxan 的位置非常好。顯然,在某些情況下,我們也有機會移除其中一個階梯療法(step therapy)的要求,但我們認為機會非常不錯。
On the question of Rx filled, we are seeing the improvement in the hepatic encephalopathy refills. We think that an important part of what we're trying to do, to improve the compliance of this program, and the team has put together some compliance programs for the future. The only real issue with Xifaxan is one that Rob mentioned -- there has certainly been some inventory adjustments between the first quarter and the second quarter as the primary major areas of difference. Go ahead.
關於處方配藥完成(Rx filled)這個問題,我們看到肝性腦病(hepatic encephalopathy)的續配(refills)有所改善。我們認為我們正在努力做的一個重要部分,是提升這個療程的依從性(compliance),而團隊也為未來制定了一些依從性方案。Xifaxan 唯一真正的問題是 Rob 提到的那一點——第一季與第二季之間確實有一些庫存調整,這是主要差異的核心原因。請繼續。
- Analyst
- Analyst
Just to be clear: Nitropress and Isuprel generic are not in the second half of assumption for the guide, right?
我想確認一下:Nitropress 和 Isuprel 的學名藥並沒有被納入指引中對下半年(second half)的假設,對吧?
- CEO
- CEO
We have them planned for the next 6 to 12 months is what we have got planned into this.
我們的規劃是未來 6 到 12 個月內會發生,這就是我們納入規劃的時間點。
- Analyst
- Analyst
All right. Thanks.
好,謝謝。
Operator
Operator
Cindy Guan, Goldman Sachs.
Cindy Guan,高盛。
- Analyst
- Analyst
Thanks. I wanted to ask on the sentence in the slide -- the restored new profitability to new derm scripts starting August 5. I was wondering, how does that timing compared to what was originally expected? Also related to that, the timing of the Relistor launch in September? And obviously the delay in Latanoprostene? On the first-quarter call, you mentioned there was some conservatism built in for both the new product launches and [fixing] Walgreens, so how does that compare to those original expectations? Are negative ACs no longer an issue? Or are there still some (inaudible) that need to be addressed?
謝謝。我想問投影片上的那句話——自 8 月 5 日起,新皮膚科處方(new derm scripts)恢復淨獲利能力(net profitability)。我想知道,這個時間點和原先預期相比如何?另外相關的是,Relistor 在 9 月上市的時間點?以及顯然 Latanoprostene 的延遲?在第一季電話會議上,你們提到對新產品上市以及(修復)Walgreens 的部分都已納入一些保守假設,那這和原先的預期相比如何?負的 AC(negative ACs)是否已不再是問題?還是仍有一些(聽不清楚)需要處理?
And then quickly, secondly, on the $5 billion debt repayment over 18 months, does that include a revolver paydown, $1.35 billion? Or all of that $5 billion is loans? My understanding is, with asset sales, that needs to go to loans; so related to that, how are you thinking about addressing on year to date 2018 unsecured bonds? Thank you.
然後很快第二個問題,關於 18 個月內償還 50 億美元債務,這是否包含循環信貸(revolver)償還 13.5 億美元?還是這 50 億美元全部都是貸款?我的理解是,若有資產出售,所得需要用來償還貸款;因此延伸來看,你們打算如何處理 2018 年到期的無擔保債券(unsecured bonds)?謝謝。
- CEO
- CEO
I will take the first two questions about net profitability with derm and the new products. Then, Linda, if you can help on that debt question specifically, and the paydown on the revolver question.
我先回答前兩個問題:皮膚科的淨獲利能力以及新產品。然後 Linda,請你協助回答那個債務問題,特別是循環信貸(revolver)償還的部分。
First of all, as we stated on the last call in June, I stated that we believed we would resolve the issues with the Walgreens program within 30 to 60 days. I will say that we have been very pleased with the cooperation we received from Walgreens. The teams are working together very well, and indeed, we did achieve the improvement in net profitability in early August. So that is right in line with the 30 to 60 days. And in fact, we actually got some of the couponing programs for the independent pharmacists out within the 30-day time frame. So everything has moved along very consistent with what we had said previously.
首先,正如我們在 6 月上次電話會議所說,我當時表示我們相信能在 30 到 60 天內解決 Walgreens 計畫的問題。我可以說,我們對 Walgreens 給予的合作非常滿意。雙方團隊合作得非常好,而且我們確實在 8 月初達成了淨獲利能力的改善。因此這完全符合 30 到 60 天的時程。事實上,我們也在 30 天的時間框架內,將一些針對獨立藥師的折價券(couponing)方案推出。所以一切進展都與我們先前所說的非常一致。
On the question of our pipeline, when I was on the call, one of the things I tried to illustrate is that we have three action dates within our pipeline that I was very excited about for the second half of 2016 on the first quarter call on June 7. Indeed, one of the things I said was that we would be very pleased and it would be good day for us if we received two out of the three, and indeed, that is what we did get. We got the Brodalumab recommendation by the advisory committee for approval, and also the Oral Relistor. It is a delay on the Latanoprostene, but we think we know what the important items are for that complete response letter. We are going to be working very closely with the FDA on those issues to get that one moving forward. But we have tried to be somewhat conservative in bringing those numbers into our plan. We're going to continue to keep that as a mindset. Until the products are launched and we are out in the marketplace, we want to be relatively conservative on new products.
關於研發管線(pipeline),我在電話會議上試圖說明的一點是:在 6 月 7 日第一季電話會議時,我對 2016 年下半年管線中三個行動日期(action dates)感到非常興奮。當時我確實說過,如果三個之中能拿到兩個,我們會非常高興,對我們來說會是好日子,而我們也確實拿到了兩個。我們獲得了諮詢委員會(advisory committee)對 Brodalumab 建議核准的結果,也拿到了口服 Relistor。Latanoprostene 則有所延遲,但我們認為我們知道那封完整回覆函(complete response letter)中重要的事項是什麼。我們會就這些議題與 FDA 非常密切合作,推動它繼續往前。但我們在把這些數字納入計畫時,已經盡量採取較保守的方式。我們會持續維持這樣的心態。在產品真正上市並進入市場之前,我們對新產品的預估會相對保守。
Last part of the question, Linda, was on debt, and--
問題最後一部分,Linda,是關於債務,還有——
- Treasurer
- Treasurer
Cindy, on the $5 billion from free cash flow and non-core asset sales, we will use that to pay down a mix of revolver, term loans, and bonds, I expect. As you know, the asset sale proceeds do need to go to pay down secured debt, so that portion of the $5 billion would go directly to our secured debts. As far as the 2018 unsecured bonds, we're focused on that maturity and want to consider that in the mix as we look to optimize the capital structure and stay in front of our maturities.
Cindy,關於來自自由現金流(free cash flow)與非核心資產出售(non-core asset sales)的 50 億美元,我預期我們會用來償還循環信貸(revolver)、定期貸款(term loans)以及債券(bonds)的組合。如你所知,資產出售所得確實需要用來償還有擔保債務(secured debt),因此這 50 億美元中的那一部分會直接用於償還我們的有擔保債務。至於 2018 年到期的無擔保債券(unsecured bonds),我們聚焦於該到期日,並希望在我們尋求最佳化資本結構、並提前管理到期結構(maturities)時,把它納入整體組合考量。
- Analyst
- Analyst
Great. Thank you very much.
很好。非常感謝。
Operator
Operator
Lennox Gibbs, TD Securities.
Lennox Gibbs,TD Securities。
- Analyst
- Analyst
Good morning.
早安。
As we think about turnaround in the existing dermatology portfolio, how should we think about the near-term revenue potential of that business? And how, perhaps, should we look at it relative to the pre-Walgreens revenue performance for the business?
當我們思考既有皮膚科產品組合的扭轉(turnaround)時,我們應該如何看待該業務短期的營收潛力?以及,或許,我們應該如何把它與該業務在 Walgreens 事件之前的營收表現做比較?
- CEO
- CEO
One of the things that is clear is that we have been looking at the new prescription levels going back historically, and we've had good success on new prescriptions. One of the things that has occurred is we've seen a lowering of some of the refill prescriptions that have occurred, but we're seeing some progress with our programs with Walgreens to help pace with this compliance. We are going to continue to work with our partner at Walgreens. We're very, as I said, happy with the interactions between Walgreens and Valeant. We think, collectively, we are going to try to find ways that help make sure patients get the medications they need in a very compliant fashion, and indeed, to work through that.
有一點很清楚:我們一直回溯歷史檢視新處方(new prescription)的水準,而我們在新處方方面表現不錯。發生的一件事是,我們看到部分續配處方(refill prescriptions)有所下降,但我們也看到與 Walgreens 合作的方案在提升這種依從性(compliance)方面有一些進展。我們會持續與 Walgreens 這個合作夥伴一起努力。正如我所說,我們對 Walgreens 與 Valeant 之間的互動非常滿意。我們認為,雙方將共同嘗試找出方法,確保病患能以高度依從的方式取得他們所需的藥物,並確實把這些問題逐步解決。
But I probably don't want to go into any specific promises on exactly what is going to happen with refill rates and/or just how we think it's going to affect the entire dermatology franchise. We are going to continue to stick with the overall comments we have made on the guidance commentary for the year, in terms of looking at what we're going to expect. But I do think the program is working with Walgreens. We're seeing good receptivity to our programs with Walgreens and it's been a good interaction with Walgreens. Once again it is a 20-year relationship with Walgreens and ourselves, so we're looking forward to continuing to improve it as we go forward.
但我可能不想就補充配藥率(refill rates)究竟會發生什麼、以及/或我們認為這將如何影響整個皮膚科事業群,做出任何具體承諾。我們將持續遵循我們在今年指引說明中所做的整體評論,來看我們預期會發生什麼。不過我確實認為這個與 Walgreens 的計畫正在發揮作用。我們看到 Walgreens 對我們的計畫反應良好,與 Walgreens 的互動也很順利。再一次強調,Walgreens 與我們之間有 20 年的合作關係,因此我們期待在未來持續改進並向前推進。
- Analyst
- Analyst
Thanks very much.
非常感謝。
Operator
Operator
Annabel Samimy, Stifel.
Annabel Samimy,Stifel。
- Analyst
- Analyst
Thanks for taking my question.
謝謝讓我提問。
I wanted to go back to two of the areas that you cited as the big problem areas, the GI and the derm right now. In GI, you mentioned that you had some sales force turnover. Where are you in terms of -- you said you stabilized the sales force. Have you put a new sales force in place to be able to get that franchise growing again?
我想回到你提到目前兩個最大的問題領域:腸胃(GI)與皮膚科(derm)。在 GI 方面,你提到銷售團隊有一些人員流動。就你說的「銷售團隊已穩定」而言,目前進度如何?你們是否已建立一支新的銷售團隊,以便讓該事業群重新恢復成長?
And for the dermatology side, with the prior authorization program with Walgreens, you've put this program in place where I believe you are trying to institute some co-pay for these dermatology prescriptions that had prior authorizations. Is that what you're talking about in terms of prior authorization programs? And if in fact it is a co-pay program that you've instituted, is that having any impact or do you expect that to have any impact on prescription fills or people walking away from prescriptions? Thanks.
至於皮膚科方面,關於與 Walgreens 的事前授權(prior authorization)計畫,你們已推行一個計畫,我理解你們是想對這些需要事前授權的皮膚科處方引入某種自付額(co-pay)。你所說的事前授權計畫指的是這個嗎?如果確實是你們導入的自付額計畫,這是否已造成任何影響,或你預期會對處方配藥(fills)或病患放棄領藥產生任何影響?謝謝。
- CEO
- CEO
First, on the stabilizing the sales force -- what my comments were really meant to say is that from the beginning parts of the year through June, we have stabilized the sales force and we've seen a reduction in turnover on the sales organization. That was really what my comment was meant to be.
首先,關於穩定銷售團隊——我剛才的評論主要是想表達:從年初到 6 月,我們已讓銷售團隊趨於穩定,並且看到銷售組織的人員流動率下降。這才是我那段話的重點。
But specifically, on your question, did we add sales resources -- yes, during that time period, we added some incremental sales reps for the Xifaxan organization. I believe it was an incremental 67%, but let me just check that -- for people who are promoting our hepatic encephalopathy. Let me check that exact number; but to be clear we did add some additional sales reps for our Xifaxan team for hepatic encephalopathy. 65% was added, the incremental number of sales reps.
但就你具體的問題:我們是否增加了銷售資源——是的,在那段期間,我們為 Xifaxan 團隊增加了一些額外的業務代表。我相信增幅約為 67%,但我先確認一下——這些人員是用來推廣我們的肝性腦病變(hepatic encephalopathy)適應症。我會再確認確切數字;但要說清楚的是,我們確實為 Xifaxan 的肝性腦病變團隊增聘了額外業務代表。新增的業務代表增幅是 65%。
On the second question of derm prior authorization programs, we have done a couple things. We did launch the program that we refer to as a prior authorization process with CoverMyMeds. They are an independent company that helps the patients through the prior authorization process, who try to make it easier for patients, easier for physicians, to receive the medications that their patients want to receive. So indeed we have launched that program. That program kicked off in August 4. That is the program I was referencing on the call. Indeed, we did look at, as we move to improve the net profitability of our dermatology prescriptions, we did look at co-pay levels and that was part of the program that we instituted in August. That did occur.
第二個問題,關於皮膚科的事前授權計畫,我們做了幾件事。我們推出了一個我們稱之為透過 CoverMyMeds 進行的事前授權流程。CoverMyMeds 是一家獨立公司,協助病患完成事前授權流程,並試圖讓病患與醫師更容易取得病患想要使用的藥物。因此我們確實已推出該計畫。該計畫於 8 月 4 日啟動,這就是我在電話會議中提到的計畫。確實,為了提升皮膚科處方的淨獲利能力(net profitability),我們也檢視了自付額(co-pay)水準,這是我們在 8 月導入計畫的一部分;這件事確實已發生。
Relative to the impact of the prescriptions, probably the best answer to that is that we're going to be monitoring that and tracking it. We have not seen anything yet, but it is obviously less than a week, so it would be too early to make any comment specifically on any impact on prescription levels, but it is something we are going to monitor very closely.
至於對處方的影響,最好的回答可能是:我們會持續監測並追蹤。我們目前尚未看到任何影響,但顯然現在還不到一週,因此就處方量的任何影響做出具體評論都還太早;不過這是我們會非常密切監控的事項。
- Analyst
- Analyst
Okay. On GI, the inventory impact -- can you quantify the impact and whether inventory should be stable on GI going forward?
好的。關於 GI 的庫存影響——你能量化其影響嗎?以及 GI 的庫存未來是否應該會保持穩定?
- CEO
- CEO
The overall inventory levels did come down. The actual number, inventory levels in terms of months on hand, has come down by approximately 0.1%, so that would be approximately less than a week, I'd say. Just in terms of a general comment.
整體庫存水位確實下降了。以「可供應月數」(months on hand)來看,庫存大約下降了 0.1%,也就是大概不到一週的量。我先做一個概括性的說明。
- Analyst
- Analyst
Thank you.
謝謝。
Operator
Operator
Chris Schott, JPMorgan.
Chris Schott,JPMorgan。
- Analyst
- Analyst
Thanks for the question. A couple of quick ones here.
謝謝讓我提問。我這裡有幾個簡短問題。
First, on the non-core asset sales, can you elaborate a little bit more on how you're considering what is core and non-core in the business? Is this based on what is able to be efficiently monetized right now? Or is this really going product or business by business, of what fits in with your vision for the Company going forward versus what is no longer part of the new Valeant?
第一,關於非核心資產出售,你能否更詳細說明你們如何界定業務中的核心與非核心?這是基於目前哪些資產能夠有效率地變現(monetized)嗎?還是你們會逐一以產品或業務為單位,判斷哪些符合公司未來願景、哪些已不再屬於新的 Valeant?
Second -- this is a follow-up on this non-core side -- based on the sales and EBITDA multiples that seem to be referenced in that slide 25, these businesses seem to have margins more in line with the durable growth segment. Is that what we should be thinking about some of these assets coming from? Or is it really across the three new segments that you laid out? Thanks very much.
第二——也是針對非核心的追問——根據投影片 25 中提到的出售價格與 EBITDA 倍數(multiples),這些業務的利潤率似乎更接近「耐久成長」(durable growth)部門。我們是否應該認為這些資產主要來自那個部門?還是其實會橫跨你們所提出的三個新部門?非常感謝。
- CEO
- CEO
Maybe a couple comments on it, Chris, and I'll get to each parts of your question. First of all, I want to make sure I said this process is an exploratory phase at this point. I'm not going to make too many comments about it, other than the comments I've said, that we have initiated the process and worked with some banks to help us explore the options in front of us.
Chris,我先就此做幾點說明,並逐一回應你的問題。首先,我想確認我已說清楚:目前這個流程仍處於探索階段(exploratory phase)。除了我已經說過的內容之外,我不會對此做太多評論;也就是我們已啟動該流程,並與一些銀行合作,協助我們探索眼前的各種選項。
Relative to the questions specifically about core products and what is core and what is non-core -- core can mean, getting back to what I said before, are several areas. Number one, it is our dermatology business is core. Number two, our eye care, or Bausch & Lomb, business is core. And then number three, our Salix, or GI business is core. In addition to that, we've also specified consumer as being a core part of what we believe we can do in terms of, once again, building durable growth businesses for the future.
至於你具體問到核心產品、以及什麼是核心與非核心——核心的定義,如同我先前所說,包含幾個面向。第一,我們的皮膚科業務是核心。第二,我們的眼科照護(eye care),也就是 Bausch & Lomb 業務,是核心。第三,我們的 Salix,也就是 GI 業務,是核心。此外,我們也明確指出消費者(consumer)業務是核心的一部分,因為我們相信我們能在該領域再次打造未來具備耐久成長的業務。
On the other part of the question, though, there's also a geographic question. We have specified that clearly the US and Canada, our home market, are core markets for us as a Company. So I will make sure I talk about both it from a core product, but also from a core geography, as important to us. On the question of where these are coming from, it really is across the portfolio rather than any individual business unit. We've looked across the portfolio at some of the assets that are potentially, as I would refer to, non-core or opportunities for us to look at future asset sales for the future.
不過,問題的另一部分也涉及地理面向。我們已清楚指出,美國與加拿大作為我們的本土市場,是公司核心市場。因此我會同時從核心產品與核心地理區域兩方面來談,這兩者對我們都很重要。至於這些資產會從哪裡來,實際上是橫跨整個投資組合,而非任何單一事業單位。我們已從整體投資組合中檢視一些資產,我會把它們稱為可能屬於非核心,或是我們未來可能考慮出售資產的機會。
Rob, anything you wanted to add to that comment?
Rob,你有沒有想補充的?
- Analyst
- Analyst
Thank you.
謝謝。
Operator
Operator
Gary Nachman, BMO Capital Markets.
Gary Nachman,BMO Capital Markets。
- Analyst
- Analyst
Joe, could you review how much you'll be able to enhance the profitability of the derm prescriptions through Walgreens? I know it just started, but order of magnitude on that would help. And how long it will take to really work through this and make all those prescriptions profitable? Then, do you still plan to do the second part of the Walgreens deal on generics later this year? Thanks.
Joe,你能否回顧一下,透過 Walgreens 你們能在多大程度上提升皮膚科處方的獲利能力?我知道才剛開始,但如果能提供一個大致量級會很有幫助。以及要花多久才能真正把這件事推進,讓那些處方都變成有利可圖?另外,你們是否仍計畫在今年稍晚推進 Walgreens 合作的第二部分,也就是關於學名藥(generics)的部分?謝謝。
- CEO
- CEO
I probably don't want to give exact details about the profitability because it's still very early. All I will simply say is, though, that we are confident that putting this program in place we are dramatically reducing the number of prescriptions that would be what I referred to previously as a negative average selling price. So we do believe that it is restoring net profitability, as I made comment in the call. On the question -- I'm sorry, the second part of this question was?
我可能不想提供獲利能力的精確細節,因為現在仍非常早期。我只能簡單說,我們有信心,透過導入這個計畫,我們正在大幅降低我先前所稱的「平均售價為負」(negative average selling price)的處方數量。因此我們確實相信,正如我在電話會議中所說,這正在恢復淨獲利能力(net profitability)。至於第二個問題——抱歉,你第二部分是問什麼?
- Analyst
- Analyst
The original second part of the Walgreens deal was supposed to be in generic later this year?
Walgreens 合作的第二部分原本是預計今年稍晚在學名藥方面推進?
- CEO
- CEO
The answer to that is, yes. We're moving forward with Plan B. We have said, though, we are working very closely with our partner on that Plan B. It is likely to be a gradual roll out of opportunities to look at the opportunity to sell our branded products for generic prescriptions. But that is a more gradual process than perhaps we had originally talked, but we are looking to move that one forward, as well, in the latter half of 2016.
答案是,是的。我們正在推進 Plan B。不過我們也說過,我們正與合作夥伴就 Plan B 非常密切地合作。這很可能會是逐步推出(gradual roll out),去探索將我們的品牌藥(branded products)用於學名藥處方(generic prescriptions)銷售的機會。但這會是一個比我們最初可能談到的更為循序漸進的過程;不過我們也希望在 2016 年下半年把這件事往前推進。
- Analyst
- Analyst
Okay. Just a quick follow-up. Based on all the recent conversations, any new branded products that could potentially be added into Walgreens once you have made some of these fixes in dermatology?
好的。再快速追問一下。基於最近所有的討論,一旦你們在皮膚科做完這些修正後,是否有任何新的品牌產品可能被納入 Walgreens?
- CEO
- CEO
I would say, in terms of new branded products, we're going to continue to work very closely with Walgreens. I don't think I'm going to identify any specific products at this time, but whether it be the Part B or other programs that we are thinking about, we will figure out, once we work through all these questions, if there's other things that will make sense to Walgreens, it makes sense to Valeant, and clearly, it makes sense for helping to improve patients' lives, by making healthcare products available. We're going to make sure we explore those options, but I don't want to go into any specifics at this time.
我會說,就新推出的品牌產品而言,我們將會繼續與 Walgreens 非常緊密地合作。我目前不打算指出任何特定產品,但不論是 Part B 或我們正在思考的其他方案,一旦我們把這些問題都釐清後,我們會判斷是否還有其他對 Walgreens 有意義、對 Valeant 也有意義,且顯然能透過讓醫療保健產品更容易取得來協助改善病患生活的事項。我們會確保探索這些選項,但目前我不想談任何細節。
- Analyst
- Analyst
Okay. All right. Thanks.
好的。好。謝謝。
Operator
Operator
Andrew Finkelstein, Susquehanna Financial Group.
Andrew Finkelstein,Susquehanna Financial Group。
- Analyst
- Analyst
Good morning and thank you for taking the question.
早安,謝謝讓我提問。
I was hoping you could talk a bit more about cash flows in the quarter. Were there any pushes and pulls and how you see yourself on track for the at least $1.7 billion in generation for the year? Then, as you gave that slide, and looking at the ability to overcome the impact of losses of exclusivity over the next couple years, are non-core assets sales contemplated in that? If you do go through with selling the $2 billion in revenue that you talked about, I assume a lot of that is the international segment that would be included, along with Bausch & Lomb, in your new segmentation. But any elaboration you could give would be helpful.
我希望你能再多談一點本季的現金流。是否有任何推遲或提前的因素?以及你如何看待自己仍在達成全年至少 17 億美元現金產生的軌道上?另外,當你展示那張投影片、並談到未來幾年克服專利到期(失去獨占性)影響的能力時,其中是否有考量出售非核心資產?如果你確實要出售你提到的 20 億美元營收規模的業務,我猜其中很大一部分會是你新分部架構中所包含的國際事業,並且會連同 Bausch & Lomb 一起納入。但若你能再多補充一些會很有幫助。
- CFO
- CFO
Two comments I'd make about the cash flows. Again, the cash flow for the quarter was $448 million. That did include a one-time legal payment around the Salix settlement. Working capital was better than it has been historically, so in that, we feel good about the cash flow.
關於現金流我有兩點評論。再次說明,本季現金流為 4.48 億美元。其中包含一筆與 Salix 和解相關的一次性法律付款。營運資金表現也比過去歷史水準更好,因此在這方面,我們對現金流感到滿意。
- CEO
- CEO
On the question of the illustrative chart that we walked through from 2016 to 2018, we did not factor any sales at this time. Obviously, until we know specifically which products it would have an impact on -- potentially some of the products that have loss of exclusivity or it could have impact in some of the other areas. But we did not factor any assets sold at this time because, as I said, at this point, we are exploring those options, but we have not factored that into the specifics on that slide. Once again, that slide for us was mostly for illustrative purposes to help you understand how we plan to look at some of the headwind/tailwinds going into the out year.
至於我們從 2016 到 2018 年所走過的那張示意圖表,我們目前並未把任何資產出售納入考量。顯然,在我們尚未明確知道會出售哪些產品之前,就無法判斷其影響——可能會影響到一些面臨失去獨占性的產品,也可能影響到其他領域。但我們目前沒有把任何資產出售納入那張投影片的具體數字中。再說一次,那張投影片主要是示意用途,幫助你理解我們如何看待未來年度的逆風/順風因素。
- Analyst
- Analyst
All right. Thanks very much.
好的。非常感謝。
Operator
Operator
Gregg Gilbert, Deutsche Bank.
Gregg Gilbert,德意志銀行。
- Analyst
- Analyst
Joe, will the new reorganized Valeant have a new name? What will the costs be associated with the reorg and how long will it take? Then secondly, I have a question on Xifaxan. Joe, what is your view on the duration of Xifaxan, given the formidable competitor that presumably met the guidance and is challenging the patents? Thanks.
Joe,重組後的新 Valeant 會有新名稱嗎?重組相關成本會是多少、需要多久?第二個問題是關於 Xifaxan。Joe,考量到那位強勁的競爭對手據稱達到指引、並且正在挑戰專利,你如何看待 Xifaxan 的產品壽命/持續期間?謝謝。
- CEO
- CEO
On the question of the reorganization, you're asking a question certainly on name. I don't have any further comment on the name. Our name is Valeant and we will stick with that name at this point. On the question -- obviously, that's something we will always continue to evaluate.
關於重組的問題,你問到名稱。對於名稱我沒有進一步評論。我們的名稱是 Valeant,目前會維持這個名稱。至於這個問題——顯然,這也是我們會持續評估的事項。
On the question of where we are with the cost of that, this reorganization is really meant to look at a couple things. Certainly, we are making some changes in the Management team and that is contemplated in our model. We're also looking at how we're going to structure our sales, but that really is more of a concept that really, this is how we think the best way to organize the Company is; how we're organizing it with these three segments of Bausch & Lomb International, the branded Rx, and then the diversified products.
至於成本方面,這次重組主要是要檢視幾件事。當然,我們正在對管理團隊做一些調整,這已經反映在我們的模型中。我們也在檢視銷售組織要如何架構,但那更像是一個概念:也就是我們認為公司最佳的組織方式;我們將以三個事業群來組織:Bausch & Lomb International、品牌處方藥(branded Rx),以及多元化產品(diversified products)。
We think those give us businesses that look at certainly sustainable, durable growth, also opportunity to grow with the Rx business, et cetera. So there's not any specific costs associated with that, other than just some of the personnel changes that we're planning. Most of that we think will be offset by the work that Rob and the finance team is doing to help us to look at as SG&A across the organization, which I would refer to as really more of a reallocation for us to open up and be able to spend more in research and development. But offsetting that by spending or getting some more efficiencies from some of the things that we think -- for example, as we look at a process where we have a chance to get cost of goods sold synergies because we are going to build one procurement organization versus the multiples that we have today. We think that is going to get us some savings that will help us to reallocate it and make it available to get a return on investment for our R&D programs.
我們認為這些能讓我們擁有具備可持續、具韌性成長的業務,同時也有機會透過處方藥業務等來成長。因此,除了我們規劃中的一些人員調整外,並沒有任何特定的重組成本。我們認為其中大部分會被 Rob 與財務團隊正在推動的工作所抵銷,他們正協助我們檢視整個組織的 SG&A;我會把這視為一種重新配置,讓我們能釋放資源、把更多投入研發。同時,我們也會透過支出控管或取得更多效率來抵銷——例如,當我們檢視流程時,我們有機會在銷貨成本上取得協同效益,因為我們將建立一個統一的採購組織,而不是像現在有多個。我們認為這將帶來一些節省,幫助我們重新配置資源,並讓其可用於我們研發計畫的投資報酬。
On the question of Xifaxan, you asked some of the questions on relative to our position. As you know, we have patents that run from 2019 to 2029. We have 22 patents in total and we feel very good about that position. Having said that, I will be clear that we do think there is an opportunity to look at a reformulation of Xifaxan to improve the patient experience, and that's one of the things that I mentioned in the call, that we're going to look at a reformulation. Tage in my R&D team already has that underway. They have got some interesting data that they are looking at to help try to reformulate the product to make it a better patient experience for the future. So I would look to us to have more to say about that in the future, but that also could have a very meaningful impact on what we believe the future of this product looks like in the entire franchise for Xifaxan.
關於 Xifaxan,你問到我們的立場。如你所知,我們的專利期限從 2019 年到 2029 年不等,總共有 22 項專利,我們對這個布局非常有信心。不過我也要說清楚,我們確實認為有機會透過重新配方(reformulation)來改善 Xifaxan 的病患使用體驗,這也是我在電話會議中提到的,我們將評估重新配方。我的研發團隊的 Tage 已經在推進這件事,他們有一些有趣的數據正在評估,嘗試重新配方,讓產品在未來能提供更好的病患體驗。因此,未來我們會再分享更多,但這也可能對我們所認為的該產品未來走向,以及整個 Xifaxan 產品線(franchise)帶來非常重大的影響。
- Analyst
- Analyst
Thanks.
謝謝。
Operator
Operator
Louise Chen, Guggenheim.
Louise Chen,Guggenheim。
- Analyst
- Analyst
Thanks for taking my question.
謝謝讓我提問。
First of all here, can you give more color on your launch plan for Oral Relistor? How much incremental sales we can see from this product? And how confident you are that the sales force can effectively promote this product, given some of the disruptions that you talked about earlier in the call?
首先,你能否更具體說明 Oral Relistor 的上市計畫?這個產品可帶來多少增量銷售?另外,考量到你在電話會議前面提到的一些干擾因素,你對銷售團隊能有效推廣這個產品的信心有多高?
Secondly here, back on [lisnayo] for a quick minute. On the CRL, was the Tampa inspection a preapproval inspection or just a regular inspection? And can you give more color on the 483s? Then lastly, Joe, given your experience at Perrigo, what can you do to help enhance Valeant's OTC drug portfolio?
第二個問題,回到 [lisnayo] 簡短問一下。就 CRL 而言,坦帕(Tampa)的查廠是核准前查廠(preapproval inspection)還是一般例行查廠?你能否更具體說明 483 的內容?最後,Joe,基於你在 Perrigo 的經驗,你能做些什麼來強化 Valeant 的 OTC 藥品產品組合?
- CEO
- CEO
Okay, Louise, I'll try to get all of them. On Oral Relistor, our plan is to launch in September. There's a major convention or meeting in mid-September that we will plan to launch the product at Oral Relistor for. The marketing team have plans in place for that launch. We have got the sales force stabilized, as I mentioned you in the call, so we do feel there is stabilization of the sales force. Obviously, it is something we will continue to keep our eyes on because it is one of the most important variables as we think about the future success of any prescription branded market. On the question of disruptions, as I said, we've got that handled. Obviously, we will continue to monitor that.
好的,Louise,我會盡量把問題都回答到。關於 Oral Relistor,我們計畫在 9 月上市。9 月中旬有一個大型年會或會議,我們計畫在那個場合推出 Oral Relistor。行銷團隊已為上市制定計畫。如我在電話會議中提到的,我們的銷售團隊已經穩定下來,因此我們確實感受到銷售團隊已趨於穩定。當然,這是我們會持續關注的事項,因為在我們思考任何處方品牌市場的未來成功時,這是最重要的變數之一。至於你提到的干擾,我說過,我們已經處理好了;當然,我們也會持續監控。
On the question of the Tampa facility, it was both a general inspection and a preapproval inspection in February 2016. Both preapproval and a general inspection occurred to my knowledge, and it was during the preapproval side that they experienced some questions that they raised. We've been working very diligently since that February time to resolve those questions as to the situation we find ourselves today with the CRL. We feel that the changes that will be required for a reinspection is something that we can get accomplished within the next six months and be ready for a reinspection at that time. So this is -- we're working very hard to try to continue to move latanoprostene bunod forward in our pipeline and get it to the market for the patients that need the improved for lowering of intraocular pressure.
關於坦帕廠的問題,據我所知,2016 年 2 月同時進行了一般查廠與核准前查廠(preapproval inspection)。在核准前查廠的部分,他們提出了一些疑問。自 2 月以來,我們一直非常努力地處理並解決這些疑問,因此才會有今天 CRL 的狀況。我們認為,為了重新查廠所需的變更,我們可以在未來六個月內完成,並在那時準備好接受重新查廠。因此,這件事——我們正非常努力,持續推進 latanoprostene bunod 在我們研發管線中的進度,並讓它能上市,提供給需要更有效降低眼內壓的病患。
On the question of OTC, I will tell you that we have got a great team here doing the OTC products. I believe that they have done a great job here in the United States, but even around the world. I don't know if there's much I can add, but certainly it's an area of focus because one of the things I believe is very important, and that is part of why I have structured the business this way, is that I do believe, from a segment point of view, that we can structure a franchise of what we refer to as durable growth assets. Those would be the Bausch & Lomb assets, the global OTC assets, some of the things we do in our international markets. We believe what makes them and brings them together is this concept of the fact that they are brands that have a durable, sustainable business for the future and they have very nice growth characteristics. The OTC team has done well before my arrival, but what I'm going to simply try to do is bring that business together as a segment and look for building a sustainable durable business for the future.
關於 OTC 的問題,我可以告訴你,我們這裡有一支很強的團隊在做 OTC 產品。我相信他們在美國做得非常出色,甚至在全球也是如此。我不確定我還能補充多少,但這當然是一個重點領域,因為我認為有一件事非常重要,而這也是我之所以用這種方式來架構業務的一部分原因:我確實相信,從事業分部的角度來看,我們可以打造一個我們所稱的「耐久成長資產」的特許經營(franchise)。這些資產包括 Bausch & Lomb 的資產、全球 OTC 資產,以及我們在國際市場所做的一些事情。我們認為讓它們成形並把它們串在一起的,是這樣一個概念:它們是具有耐久性、可持續的未來業務的品牌,並且具備非常好的成長特性。OTC 團隊在我到任之前就做得很好,而我接下來要做的,就是把這項業務作為一個分部整合起來,並尋求為未來建立一個可持續、耐久的業務。
I think I've got all your questions, Louise.
我想我已經回答了你所有的問題,Louise。
- Analyst
- Analyst
Thank you.
謝謝。
Operator
Operator
Doug Miehm, RBC Capital Markets.
Doug Miehm,RBC Capital Markets。
- Analyst
- Analyst
It's Joel on for Doug. A quick question. I'm wondering if you can outline the co-pay changes to patients that were not receiving prior authorization approval, and outline how co-pays have changed for Jublia? We saw them increase from $0 to $35 now, that's correct?
我是 Joel,代 Doug 提問。一個簡短的問題。我想請問你能否概述一下,對於未獲得事前授權(prior authorization)核准的病患,共付額(co-pay)有哪些變動,並說明 Jublia 的共付額如何改變?我們看到它從 0 美元提高到現在的 35 美元,這是正確的嗎?
- CEO
- CEO
We did need to make some adjustment in the co-pays, that is correct. I don't think I'm going to go through the specific ones because there is some variability, so it's probably best, at this point, to make mention of the fact that we did make adjustments in the co-pays. The co-pay changes were, once again, specifically for places where patients have a prior authorization process in before they receive the drug, and we were allowing Walgreens to fill that prescription. That's a place where we did make some changes in prior authorization and the co-pays required.
我們確實需要對共付額做一些調整,這是正確的。我想我不會逐一說明具體項目,因為其中存在一些差異性,所以目前最好只是提到:我們已經對共付額做了調整。這些共付額的變更,再次強調,是針對那些病患在拿到藥之前需要先走事前授權流程的情況,而我們先前允許 Walgreens 配藥。就在這一塊,我們對事前授權以及所需的共付額做了一些變更。
- Analyst
- Analyst
Okay. Thank you. Could you outline what the new process is for the PA patients now?
好的,謝謝。你能否說明一下,現在針對 PA 病患的新流程是什麼?
- CEO
- CEO
Sure. There is really essentially three types of patients. Patient A is a cash-paying patient. That cash-paying patient, we did put a price for our products that make it available on a cash basis for those patients. The second type of patient is a patient that has insurance. They may or may not have a requirement for prior authorizations. If there is a prior authorization requirement -- let's say there's no requirement, first. Those will go through in terms of a normal covered prescription. They have various co-pay requirements depending on their individual plan.
當然。基本上大致有三種類型的病患。A 類病患是自費病患。對於自費病患,我們為產品設定了一個價格,使這些病患可以用自費方式取得。第二類病患是有保險的病患。他們可能需要、也可能不需要事前授權。如果有事前授權要求——我們先假設沒有要求。那麼這些處方就會以一般的保險給付處方流程進行。他們的共付額要求會依各自的保險方案而有所不同。
It is the third category where we had some previous negative average selling price, where there was a prior authorization requirement, and until that requirement was met, we were allowing the prescriptions to flow through. But at this point we're going to continue to allow those prescriptions to flow through, but there will be a co-pay requirement for that prescription. That is perhaps the area that had the most questions and in how we've been working with our partner Walgreens to resolve that.
第三類才是我們先前出現一些負的平均售價(average selling price)的情況:存在事前授權要求,而在該要求尚未滿足之前,我們仍允許處方繼續流轉。但目前我們仍會繼續允許這些處方流轉,不過該處方將需要共付額。這可能就是引發最多疑問的部分,也是我們一直與合作夥伴 Walgreens 一起努力解決的地方。
- Analyst
- Analyst
Perfect. Thank you.
非常好,謝謝。
Operator
Operator
Douglas Tsao, Barclays.
Douglas Tsao,Barclays。
- Analyst
- Analyst
Good morning. Thanks for taking the questions.
早安,謝謝讓我提問。
First, Joe, in terms of the reformulation of Xifaxan that you just mentioned, is that geared towards one of the indications, IBSD or HE?
首先,Joe,關於你剛才提到的 Xifaxan 重新配方(reformulation),這是針對哪一個適應症,IBSD 還是 HE?
- CEO
- CEO
Really what it is meant to do, Doug, is to look at the current Xifaxan formulation and look to find avenues of pursuit that will improve the patient experience with the product, whether it be for HE or IBSD. It is really intentive, because the action of this drug is predominantly local action in the GI tract and with very little absorbed, we do believe there's an opportunity to reformulate this and get an improved patient experience across any indication for Xifaxan. So look to us to spend more time and more comments on that, but that is the concept. What can we do this product to help improve the patient experience? We think a reformulation could help improve that for the future for patients and that is what we're spending some time and effort on. Tage and the team already has some early data and we will look to have more comments on that in the future.
Doug,這項工作的目的其實是檢視目前的 Xifaxan 配方,並尋找可追求的途徑,以改善病患使用該產品的體驗,不論是針對 HE 或 IBSD。這是非常有意圖的,因為這個藥物的作用主要是在腸胃道(GI tract)的局部作用,吸收量非常少;因此我們確實相信有機會透過重新配方,讓 Xifaxan 在任何適應症上都能帶來更好的病患體驗。所以請期待我們之後投入更多時間並提供更多評論,但概念就是如此:我們能對這個產品做些什麼來幫助改善病患體驗?我們認為重新配方可能有助於在未來改善病患的使用體驗,這也是我們正在投入時間與精力的方向。Tage 和團隊已經有一些初步數據,我們未來也會就此提供更多說明。
- Analyst
- Analyst
Okay. Great. Then in terms of the dermatology business, what percentage of the overall volume is now going through Walgreens versus some of the other channels? Then also, ex-US business, both emerging markets, as well as developed, look to be much better than we were expecting. Was there any particular countries or product lines that are worth calling out so we can understand things and trends for the second half of the year? Thank you.
好的,很好。那麼就皮膚科業務而言,目前整體量有多少比例是透過 Walgreens,而不是其他通路?另外,美國以外(ex-US)的業務,無論是新興市場或已開發市場,看起來都比我們預期好很多。是否有任何特定國家或產品線值得特別點出,讓我們能理解下半年趨勢?謝謝。
- CEO
- CEO
Right now -- let me answer the first question -- approximately 50% of our dermatology business is working through the Walgreens program. That was the first part of your question. Then, Rob, do you want to get this inquiry, it was the emerging markets question. Do you want to handle that particular question?
目前——我先回答第一個問題——我們大約 50% 的皮膚科業務是透過 Walgreens 計畫在運作。這是你問題的第一部分。接著,Rob,你要不要回應這個提問?這是關於新興市場的問題。你要不要處理這個問題?
- CFO
- CFO
China continues to perform very well. Asia overall performs very well. Certain countries in Europe have gone very well. Mexico in Latin America, while there have been challenges in other parts of Latin America, Mexico has been a very strong performer.
中國持續表現非常好。整體亞洲表現也非常好。歐洲某些國家表現很不錯。拉丁美洲方面,雖然拉美其他地區有一些挑戰,但墨西哥一直是非常強勁的表現者。
- Analyst
- Analyst
Your expectation, Rob, that, that should continue into second half of the year?
Rob,你的看法是,這樣的表現應該會延續到下半年嗎?
- CFO
- CFO
As I mentioned, remember last time, when we corrected for the inventory shift that we made in Q1, there was a healthy growth in the emerging markets, and as you will see from the press tables, that has continued and we do expect that to continue for the second half.
如我所提到的,請記得上次我們說過,當我們把第一季所做的庫存轉移(inventory shift)影響校正後,新興市場其實有健康的成長;而你也會從新聞稿的表格中看到,這樣的趨勢已經延續,我們也預期下半年會持續。
- Analyst
- Analyst
Okay. Great. Thank you very much.
好的,很好。非常感謝。
Operator
Operator
Irina Koffler, Mizuho.
Irina Koffler,Mizuho。
- Analyst
- Analyst
Thanks for taking the questions.
謝謝讓我提問。
Your developed markets business and your US business is actually flat to down, Q-over-Q, which is somewhat different from other companies in the sector, which traditionally have a weaker first quarter and then rebound back after deductibles have been eased off of. Just wondering why we should have conviction in the business rebounding in the back half the year when Jublia is down quarter-over-quarter, the GI business is essentially flat, and Xifaxan is down Q-over-Q.
你們的已開發市場業務以及美國業務,按季(Q-over-Q)其實是持平到下滑,這與同業有些不同;同業通常第一季較弱,之後在自付額(deductibles)壓力緩解後會反彈。我想知道,當 Jublia 按季下滑、GI 業務基本持平、而 Xifaxan 也按季下滑時,我們為什麼應該對下半年業務反彈有信心?
So the first question is, what is really going to put the steam behind this business in the second half of the year? Then the second question I had was around the $8 billion in divestitures. You outlined some divestitures today in your press release and they were structured as a little bit in upfront payments and then a lot in backloaded milestones, so do we have conviction that if you were to get the $8 billion, you would get it all upfront in cash, or that a lot of it would be backloaded? Thank you.
所以第一個問題是:到底是什麼會在下半年為這個業務提供動能?第二個問題是關於 80 億美元的資產剝離(divestitures)。你們今天在新聞稿中概述了一些剝離交易,其結構是部分前期付款(upfront payments),以及大量後置的里程碑款(backloaded milestones)。因此,如果你們要達到 80 億美元,我們是否有信心能以現金一次性在前期拿到,還是其中很大一部分會是後置的?謝謝。
- CEO
- CEO
Let me start with the question on developed markets and the sequential results. Number one, as we've looked at the revenue, just to be point out, the revenue, year-to-date, we are at 48% of the revenue guidance for the full year. It does not take a big increase in revenue, of course, to really reflect the -- while we expect some, we're at 48% and we're halfway through the year on revenue. Just first comment on revenue for the first half.
我先從已開發市場以及按季表現的問題開始。第一,當我們檢視營收時,先指出一點:年初至今,我們已達到全年營收指引的 48%。當然,要反映——雖然我們預期會有一些增長——其實不需要很大的營收增幅;我們目前是 48%,而時間也已經過了半年。這是我對上半年營收的第一個評論。
On the second question, though, obviously there other things we're taking steps to do. Rob made mention of some of things that we're looking at in terms of the -- one of the things that we're doing on SG&A and how we're looking at the SG&A in organization, and importantly, how we're reallocating some dollars towards R&D. Those are all things that we think are important parts for our second half.
至於第二個問題,顯然我們也在採取其他步驟。Rob 提到了一些我們正在看的事項,包括我們在 SG&A 上所做的事情、以及我們如何看待組織中的 SG&A;更重要的是,我們如何把部分資金重新配置到研發(R&D)。我們認為這些都是下半年很重要的組成部分。
The one other comment I want to reflect on is that, as we've made mention to a previous caller, we also did see some reductions in inventory month on hand, moving from the first quarter to the second quarter. That is not something we expect to see forever, so that when you correct for that, that is partially how you get some incremental opportunities to look at what is going to happen in the second half of the year.
我還想補充一點:正如我們先前對一位來電者提到的,我們也確實看到庫存月數(inventory month on hand)從第一季到第二季有所下降。這不會是我們預期永遠都會發生的事情,因此當你把這個因素校正後,這也部分解釋了為什麼我們能看到一些增量機會,來評估下半年會發生什麼。
I am going to go to your upfront milestones question, but Rob, anything else you want to add to this commentary on the first half or the second half?
我先回到你關於前期里程碑的問題,不過 Rob,你還有沒有什麼想補充的,針對上半年或下半年的這段評論?
- CFO
- CFO
I agree with what Joe said. Obviously, the steam will come from dermatology, as well as Salix; and overall execution, I'd say, across the business. There obviously were bright spots in the developed markets in consumer, US contact lens; GI, obviously, year-over-year, still having growth, but as we said on the Q1 call, we think there is more opportunity there.
我同意 Joe 說的。顯然,動能將來自皮膚科以及 Salix;整體而言,我會說是全公司層面的執行。當然,在已開發市場的消費品、美國隱形眼鏡方面也有亮點;GI 方面顯然年對年仍在成長,但正如我們在 Q1 電話會議上所說,我們認為那裡還有更多機會。
- CEO
- CEO
Right. That is really what you've tried to illustrate in your guidance commentary on some of the tailwinds for that second half. O
對。那正是你在指引評論中試圖說明的、下半年的一些順風因素。O
n the question of the $8 billion and what is received upfront versus milestones, it's probably important to say every deal is a different deal. In the deals that we announced or we put into the presentation today, you are absolutely correct, there was much of it was in upfront, but there were some significant sales and approval milestones in the deal structure. I would say that, that was specific to the things that we had, that were in this particular segment for selling. Clearly, some of them, like Brodalumab, there is obviously sales milestones when the product is approved. That's something that is going to happen. It's not existing end-market product.
n 關於 80 億美元以及前期收取與里程碑之間的差異,可能重要的是要說,每一筆交易都是不同的。在我們今天宣布或放進今天簡報的交易中,你完全說得對,其中很大一部分是前期款,但在交易結構中也有一些重大的銷售與核准里程碑。我會說,那是針對我們在這個特定出售區塊中所擁有的項目而設計的。很明顯地,有些像 Brodalumab,在產品獲准後就會有銷售里程碑。那是將會發生的,因為它不是既有的終端市場產品。
That differs dramatically from what we're looking at in terms of the $8 billion potential that we're exploring options for, where these are currently marketed products. So clearly, that is the difference in structure that is appropriate for what we announced today, but may not be appropriate for what we're thinking about in terms of the future asset sales that we are contemplating. Is that understandable?
這與我們正在探索選項的 80 億美元潛在交易有很大不同,因為那些是目前已在市場上銷售的產品。因此,很明顯地,這就是結構上的差異:我們今天宣布的內容適用那樣的結構,但對於我們正在思考、未來可能進行的資產出售,未必適用。這樣說清楚嗎?
- Analyst
- Analyst
Yes. Thank you.
是的。謝謝。
Operator
Operator
David Steinberg, Jefferies.
David Steinberg,Jefferies。
- Analyst
- Analyst
I wanted to loop back on the subject of sales force turnover, given the importance of customer facing. What if anything have you done to retain sales people and how would you classify morale among the sales force? Then, broadly speaking, in the Corporation, what attrition rate have you seen this year? I know, give or take nine months ago, the Company instituted a one-year retention package, largely skewed towards senior executives. Have you had to re-up or are you considered doing that?
我想回到銷售團隊流動率這個主題,考量到面向客戶的重要性。你們為了留住業務人員做了哪些事(如果有的話)?你會如何評估銷售團隊的士氣?另外更廣泛地,在公司整體,今年你們看到的離職率是多少?我知道大約九個月前,公司推出了一年期留任方案,主要偏向高階主管。你們是否需要續推,或正在考慮再推出一次?
Just quickly, on your forecast, for Bausch & Lomb, you look at 6% to 8% revenue growth and for derm and GI, 5% to 10% for the next year. Just curious what the mix of price and volume would be on those forecasts?
另外很快問一下你們的預測:對 Bausch & Lomb,你們看 6% 到 8% 的營收成長;對皮膚科與 GI,明年是 5% 到 10%。想請教在這些預測中,價格與量的組合大概會是什麼?
- CEO
- CEO
David, I'm going to try to get all of them, but if I miss any, I'm sure you let me know, David.
David,我會盡量把問題都回答到,但如果我漏了任何一個,我相信你會提醒我,David。
First of all, turnover and morale, I do believe that we have made some improvements in the turnover, as I made mention, through the data that we have through June. It is something, though, that is very important. It's something that we are going to continue to track very closely because it is what -- the relationship that -- especially, in our very targeted markets where we have significant market share and also good relationships with our physicians, if we are going to be successful, it is because of those relationships we have with our physicians, in terms of how we bring our products to market and how we can help those physicians identify unmet medical needs. So it is important.
首先談流動率與士氣。我確實相信我們在流動率方面已有一些改善,正如我提到的,我們有截至 6 月的數據。這仍然非常重要,我們會持續非常密切地追蹤,因為這關乎——尤其在我們高度聚焦的市場中,我們擁有顯著市占,也與醫師建立良好關係——如果我們要成功,正是因為我們與醫師之間的關係:我們如何把產品推向市場,以及如何協助醫師辨識未被滿足的醫療需求。所以這很重要。
We have been monitoring it. The business unit leaders have done a very nice job of getting close to their individual district managers and regional managers. It's something that we're going to continue to work very closely on because I do believe, as I mentioned on my very first call, it's part of this rerecruiting our employees to the Valeant Company.
我們一直在監測。各事業單位領導者在貼近各自的區域經理與大區經理方面做得很好。我們會持續非常緊密地推動這件事,因為我確實相信,正如我在第一次電話會議上提到的,這是重新招募員工回到 Valeant 公司的一部分。
On the question of overall morale, I probably am not the best one to make mention of it, because I've only been here three months, but I do think that we have made progress. We've made progress every single day as we get new products approved, as we make progress in working very hard to improve patients' lives. I believe that's what's going to be the real important driver to this Company. Because yes, it's a job, but more importantly, it's about making a difference in the patients' lives. That is most important thing that I keep reminding the Company about, in terms of where we're going and what direction we are taking and how we're going to become a trusted healthcare partner. So I do believe that's the way I'm trying to address the question of morale and the challenges we face.
至於整體士氣,我可能不是最適合評論的人,因為我才來三個月,但我確實認為我們已經取得進展。我們每天都在進步:新產品獲批、我們非常努力地改善病患生活。我相信那才會是推動這家公司的真正重要動力。因為是的,這是一份工作,但更重要的是對病患生活帶來改變。這是我一直提醒公司最重要的事:我們要往哪裡走、我們採取什麼方向、以及我們將如何成為值得信賴的醫療保健夥伴。所以我認為,這就是我試圖回應士氣問題以及我們面臨挑戰的方式。
At the senior leadership side, there has been, with the exception of the announcements, some of the changes that I've announced just yesterday, there has been very limited turnover. But it is something, that, as I said, we're trying to make some changes in the new Management structure, especially as we look at the new reporting segments of the business and how we're putting together the business for the future. But I do believe that's very important to our future, because it will provide the investors and the analysts greater transparency into what we're doing for the Company.
在高階領導層方面,除了我昨天剛宣布的一些變動之外,整體流動非常有限。但正如我所說,這也是我們在新管理架構中嘗試做出一些調整的原因,特別是當我們檢視新的事業報告分部,以及我們如何為未來重整業務。我確實相信這對我們的未來非常重要,因為它將為投資人與分析師提供更高的透明度,讓大家更清楚我們在為公司做什麼。
Rob, did I miss anything that you want to contribute to?
Rob,我有漏掉你想補充的任何內容嗎?
- CFO
- CFO
Not on that one, but do you want to get to the segment growth on the--?
那一題沒有,不過你要不要談一下分部成長那個——?
- CEO
- CEO
Yes, why don't you take that one?
好,你來回答那題吧?
- CFO
- CFO
On the two, what I'd say is both the B&L and international segment and the branded segment have strong, either high single-digit top-line growth and leverage to the EBITDA growth. The B&L is being driven by the emerging market growth, which we've talked about and will continue to drive it, as well as where we stand in terms of the various technologies.
就這兩個分部而言,我會說 B&L 與國際分部,以及品牌分部,都有強勁的營收成長(高個位數),並且對 EBITDA 成長具有槓桿效應。B&L 的成長主要由新興市場成長所帶動,我們已經談過也會持續推動,另外也包括我們在各項技術上的布局與地位。
In terms of the price volume, the price assumptions are quite modest, as we have said, but getting back on doing appropriate pricing is something that the Corporation will get back to. The second, I'd say, is that the two years that we picked out, you have the issue of where is the pipeline and where is the launch and where is Broda? Again, I would end by saying both of these will provide a good robust growth looking forward beyond 2018.
就價格與量而言,如我們所說,價格假設相當保守;但回到「做出適當定價」這件事,公司會重新回到正軌。第二點,我會說,我們挑出的這兩年,會面臨管線在哪裡、上市時點在哪裡、以及 Broda 在哪裡的問題。最後我仍要說,這兩者都將在 2018 年之後,為未來提供良好且強勁的成長動能。
- Analyst
- Analyst
Thank you, Rob.
謝謝你,Rob。
Operator
Operator
Alan Ridgeway, Scotiabank.
Alan Ridgeway,Scotiabank。
- Analyst
- Analyst
Good morning, guys. Thanks for taking the questions.
各位早安。謝謝讓我提問。
Two questions from me this morning. First of all, we are now over a year since Salix was acquired and pulled into the business and we're still talking about inventory. Is inventory now finally where it should be? And can we start to follow the Xifaxan and some of the other products more directly based on demand, as opposed to having these inventory issues every quarter? And maybe a comment on where rest of world inventory sits at this point because that was an issue in Q1, as well?
我今天早上有兩個問題。第一,我們收購 Salix 並納入業務已經超過一年了,但我們仍在談庫存。庫存現在終於回到應有水位了嗎?我們是否可以開始更直接地依據需求來追蹤 Xifaxan 與其他一些產品,而不是每一季都受到這些庫存問題影響?另外也請評論一下目前世界其他地區的庫存狀況,因為那在 Q1 也是個問題。
Then secondly, just on Xifaxan, you talk about 98% covered lives, but clearly they are prior auths and step therapy required for a number of those. Can you tell us what percentage of those covered lives have prior auth and step therapy? And on the one big win, Joe, that you talk about on managed care and having some of those step therapies removed, how meaningful is that win? How many patients, how many covered lives were covered by that win? I'll leave it at that. Thanks.
第二,關於 Xifaxan,你們提到 98% 的涵蓋人數(covered lives),但顯然其中不少需要事前授權(prior auth)與階梯療法(step therapy)。你們能否告訴我們,在這些涵蓋人數中,有多少比例需要事前授權與階梯療法?另外,Joe,你提到在管理式醫療方面的一個重大勝利、移除了一些階梯療法要求,這個勝利有多重要?涵蓋了多少病患、多少涵蓋人數?我就問到這裡。謝謝。
- CEO
- CEO
I'm going to try to take them each in order. I will start with the inventory questions, and I'll give you my comment, but Rob, please feel free to join in on this comment. Number one, on the inventory question, as I mentioned, what I was really referring to is the overall inventory. It was not specifically addressed to Xifaxan, but clearly Xifaxan being our largest product has obviously some impact. But as I said, the inventory adjustment was approximately 0.1 months, so it's not a big change. I said it was less than a week, so just to give you some sense of -- it's not a big change, but it did come down slightly in the quarter.
我會依序逐一回答。我先從庫存問題開始,我會先給出我的看法,但 Rob 也請隨時加入補充。第一,關於庫存問題,正如我提到的,我真正指的是整體庫存,並不是特別針對 Xifaxan;但很明顯,Xifaxan 作為我們最大的產品,當然會有一些影響。不過如我所說,庫存調整大約是 0.1 個月,所以不是很大的變化。我說過不到一週,讓你有個概念——變動不大,但本季確實略有下降。
Rest of world inventory -- Rob, anything you'd add to the rest of world?
世界其他地區的庫存——Rob,關於世界其他地區,你還有什麼要補充的嗎?
- CFO
- CFO
You'll read about it in the Q. We obviously talked and disclosed about it. We continue to monitor those around the world and they are continuing to come down, as we disclosed in the Q1 Q.
你會在Q裡讀到。我們當然已經談過並揭露了這件事。我們持續監控全球各地的情況,而且正如我們在第一季Q中揭露的,它們仍在持續下降。
- CEO
- CEO
On the question of the 98% covered lives, you're absolutely correct. In the -- give you some specifics: we have 68% unrestricted, and that is approximately 20 million lives. But the prior authorizations largely are part of whether it's the hepatic encephalopathy indication or it's the IBSD. Specifically, on the question that the wins that I was referring to -- actually it was more than one win, I just pointed to a win, but it is actually wins with two very large customers. Those also affect somewhere around 20 million lives for two very large customers that occurred, starting on or about August 1 in terms of timing. So that's where we made progress with two very large customers, affecting 20 million lives, that removes some of the step edits, starting August 1.
關於98%涵蓋人數(covered lives)這個問題,你完全正確。在——我給你一些具體數字:我們有68%是無限制(unrestricted)的,約為2,000萬人。但事前授權(prior authorizations)在很大程度上取決於是肝性腦病變(hepatic encephalopathy)的適應症,或是IBSD。具體來說,關於我所提到的那些勝利——其實不只一個勝利,我只是指出其中一個,但實際上是與兩個非常大的客戶取得的勝利。這些也影響到約2,000萬人,涉及兩個非常大的客戶,時間上大約從8月1日左右開始。因此,我們在兩個非常大的客戶上取得進展,影響2,000萬人,自8月1日起移除部分階梯式編輯(step edits)。
- Analyst
- Analyst
Are those step edits specifically on the IBS side or on both the HE and the IBS side, in general?
那些階梯式編輯是特別針對IBS端,還是一般而言同時涵蓋HE與IBS兩端?
- CEO
- CEO
They are actually on both. They are actually on both.
其實兩者都有。其實兩者都有。
- Analyst
- Analyst
Great. Thanks.
很好。謝謝。
- CEO
- CEO
In one case, it was a reduction of a need for a step edit for a loperamide or anti-spasmatic for IBSD prior authorization. That was one of the removal of step edits, as an example, for IBSD.
其中一個案例是,針對IBSD的事前授權,降低了需要先做洛哌丁胺(loperamide)或抗痙攣藥(anti-spasmatic)的階梯式編輯要求。這是移除IBSD階梯式編輯的一個例子。
Operator
Operator
David Common, JPMorgan.
JPMorgan的David Common。
- Analyst
- Analyst
It's David Common. Thanks for the extended Q&A. I really think it's the right thing to be doing.
我是David Common。謝謝你們延長Q&A。我真的認為這樣做是對的。
I have two questions and two clarifications. The two questions are, did the changes you just outlined to the co-pays resolve the negative ASP issue that you had for your derm products? My second question is, can you remind us, really, what is in your expectations on timing for competition for the handful of really highest margin neuro products, which became controversial on account of their pricing?
我有兩個問題和兩個釐清。兩個問題是:你們剛才概述的自付額(co-pay)變更,是否解決了你們皮膚科產品的負向ASP問題?第二個問題是:你能提醒我們,你們對於少數幾個毛利率最高、且因定價而引發爭議的神經科產品,其競爭出現的時間點預期是什麼?
And then the clarifications: if I have this right, your $5 billion of debt reduction on the next 18 months -- is that $3 billion to $3.5 billion from cash flow, and then just assuming a very small subset of the potential asset sales you have called out? And this is for Linda: I see on the press really just a small reduction in the senior notes quarter over quarter. Is that possible that, that would be open market repurchases, and really, what is your view on that for free cash flow? Thank you.
然後是釐清:如果我理解正確,你們未來18個月要減少50億美元的債務——其中30億到35億美元來自現金流,然後只是假設你們所提到的潛在資產出售中有非常小的一部分會發生?另外這題給Linda:我看到新聞稿上資深票據(senior notes)季對季只小幅下降。是否可能是公開市場回購?以及你對自由現金流(free cash flow)在這方面的看法是什麼?謝謝。
- CEO
- CEO
Okay. First of all, thank you for the comment on the extended Q&A. We do think it's important to try to be as transparent as possible and why we've extended the Q&A.
好的。首先,謝謝你對延長Q&A的評論。我們確實認為,盡可能透明很重要,這也是我們延長Q&A的原因。
On the questions, a couple of them -- the first question was do the co-pay changes reduce the situation with negative average selling price? The answer to that is yes.
關於問題,其中幾個——第一個問題是自付額變更是否降低了負向平均銷售價格(negative average selling price)的情況?答案是肯定的。
On the questions of the expectations, you asked about the highest margin products, in terms of when we will lose exclusivity on those. As I mentioned, we believe we will lose exclusivity on those products really in the next 6 to 12 months. Most specifically, the product Nitropress is the one we expect to lose exclusivity on first, followed by Isuprel. Both of those are in the neurology business, or what we referred to in the call, thinking forward, the diversified business. But within the next 6 to 12 months is our expectations for Nitropress and Isuprel.
關於預期的問題,你問到毛利率最高的產品,何時會失去獨占性(lose exclusivity)。如我提到的,我們認為這些產品確實會在未來6到12個月內失去獨占性。最具體而言,我們預期最先失去獨占性的是Nitropress,接著是Isuprel。這兩個都屬於神經科業務,或如我們在電話會議中所稱、往前看屬於多元化業務(diversified business)。但對Nitropress與Isuprel而言,我們的預期是在未來6到12個月內。
Finally, there was a question, Linda, for--
最後,還有一個問題,Linda,關於——
- Analyst
- Analyst
The $5 billion expectation assumes just a small portion of those potential asset sales. Is that right?
50億美元的預期只是假設那些潛在資產出售中的一小部分,對嗎?
- CEO
- CEO
I'll take that one. Yes, that was both from operational EBITDA and asset sales, was the $5 billion, but it is a smaller portion that we felt was asset sales, that is correct. Your assumption is correct. Then, Linda, there was a question, though--
我來回答。是的,50億美元是來自營運EBITDA與資產出售兩者,但我們認為資產出售只占較小部分,這是正確的。你的假設是正確的。然後,Linda,還有一個問題——
- Treasurer
- Treasurer
The last one, you asked about the senior notes. No, we did not do any repurchases of senior notes this quarter. The one thing to remember on the balance sheet is, it is book value and we have euro debt, which fluctuates based on currency.
最後一題,你問到資深票據。不,我們本季沒有進行任何資深票據的回購。資產負債表上要記得的一點是,它是帳面價值(book value),而且我們有歐元債務,會因匯率而波動。
- Analyst
- Analyst
All right. Good reminder. Thank you.
好。提醒得很好。謝謝。
Operator
Operator
David Risinger, Morgan Stanley.
Morgan Stanley的David Risinger。
- Analyst
- Analyst
Thanks very much. I started off by asking one question and then since everybody asked six, I have to ask five more.
非常感謝。我一開始只打算問一個問題,但既然大家都問了六個,我就得再問五個。
- CEO
- CEO
(Laughter) We appreciate your discipline in the first [one]. David, we appreciate the discipline.
(笑聲)我們感謝你在第一個問題上的自律。[第一個] David,我們感謝你的自律。
- Analyst
- Analyst
I'll just ask a few here.
我就問幾個。
First of all, in terms of negative ASP, could you explain what you mean by that, Joe? I've never understood that -- how a product can have negative revenue? Then second, with respect to the improvement in net profitability in early August, obviously that was within a week. Could you just explain, maybe in more technical terms, exactly how the profitability changed overnight? Obviously, it has, because you have stated it, but I don't quite understand that, either? Finally, one of the slides indicates that you plan to return to inorganic growth in 2018 and beyond. Could you talk little bit about that, as well?
首先,關於負向ASP,Joe,你能解釋一下你指的是什麼嗎?我一直不明白——一個產品怎麼可能有負的營收?第二,關於8月初淨獲利能力的改善,顯然那是在一週內發生的。你能否用更技術性的方式解釋一下,獲利能力究竟是如何在一夜之間改變的?顯然確實改變了,因為你已經說了,但我也不太理解。最後,有一張投影片顯示你們計畫在2018年及之後回到非有機成長(inorganic growth)。你也能談談這點嗎?
- CEO
- CEO
Let me explain the first comment, negative ASP. What I was referring to there -- and let be first and foremost very clear, that was referring to a comment that I made during the first quarter earnings call on June 7. What I was referring to at that time was a situation where we were allowing prescriptions to flow through the process at Walgreens if the prior authorization was not approved. For that reason, we were not receiving any cash for that prescription; however, we were still paying fees for that prescription. As a result of that, I referred to it as a negative average selling price because we received no cash for the prescription, but we were allowing the prescription to flow through and paying the fees. That is something that I made mention of we would get corrected in 30 to 60 days. Now, as I mentioned, we now believe we have that corrected based on the new programs we put in place that kicked off in early August.
我先解釋第一點,負向ASP。我在那裡指的是——而且讓我首先非常清楚地說,那是我在6月7日第一季財報電話會議中所做評論的延伸。我當時指的是一種情況:如果事前授權未獲核准,我們仍允許處方在Walgreens的流程中繼續通過。因此,我們沒有收到該處方的任何現金;然而,我們仍需為該處方支付費用。基於此,我把它稱為負向平均銷售價格,因為我們沒有收到處方的現金,但仍讓處方通過並支付費用。我當時提到我們會在30到60天內修正。現在,如我所說,我們相信基於我們在8月初啟動的新方案,這個問題已經修正。
Is that part clear, David, in terms of the negative ASP questions?
David,關於負向ASP的問題,這部分清楚嗎?
- Analyst
- Analyst
Yes. That's clear. Thank you.
是的,很清楚。謝謝。
- CEO
- CEO
On the second part of the question, that is the basis by which I've made the comment that we will have net profitability with our prescriptions because we will ensure that the co-pays that patients pay will cover the fee structure, even during the time period if we do not receive the initial approval for that prior authorization. So the co-pays will cover those fees and that will allow us to avoid the situation with negative ASPs. Is that clear?
關於第二部分,這也是我之所以評論我們的處方將具備淨獲利能力的基礎,因為我們會確保病人支付的自付額能涵蓋費用結構,即使在我們尚未取得該事前授權初始核准的期間也是如此。因此,自付額將涵蓋那些費用,這將使我們避免負向ASP的情況。這樣清楚嗎?
- Analyst
- Analyst
Yes.
是的。
- CEO
- CEO
Then on the final question -- what I said, I want to be clear, it's 2018 and beyond -- I said that we would look at a more balanced growth profile where we assume that we will pay down our debt. We will get to a manageable debt level, and at that point, when we're at a manageable debt level, we would look at trying to grow the business both organically, through our own research and development, but also through inorganic means. Because we believe we have very important franchise positions with the products in dermatology, with the products in gastro, in eye care. We believe we have very important relationships, very important positions where we have got a great pipeline. Plus, there are some places where some of our competitors and other players in the marketplace may have a product that we think makes a lot of sense.
最後一個問題——我說的是2018年及之後——我說我們會尋求更平衡的成長輪廓,前提是我們會償還債務。我們會把債務降到可管理的水準,而當我們達到可管理的債務水準時,我們會考慮透過有機方式(也就是我們自己的研發)以及非有機方式來推動業務成長。因為我們相信,我們在皮膚科、腸胃科、眼科照護等產品上擁有非常重要的特許經營地位(franchise positions)。我們相信我們有非常重要的關係與非常重要的市場地位,並且我們有很好的產品線(pipeline)。此外,市場上也有一些地方,我們的競爭對手或其他參與者可能有某些產品,我們認為非常合理。
And if we have a leadership position, for example, in GI --we just announced the Norgine relationship that w have, as a perfect example. We have a position in the GI category. Norgine has a product. We felt that would be a perfect example of us going out, and through inorganic means, building a stronger pipeline for the future. That is what I was really referring to in 2018 and beyond. I'm not making any comments yet about what percentage will be organic, what percent inorganic, but that concept, once we get to a state where we get our debt position to a more manageable place, we do believe there's going to be opportunities for inorganic opportunities. But clearly we have got a lot of debt payment downs to happen first. I don't want to get too far ahead of that transformation stage.
而且如果我們在例如GI領域擁有領導地位——我們剛宣布與Norgine的合作關係,就是一個完美例子。我們在GI類別中有既有地位,Norgine有一個產品。我們認為這正是我們走出去、透過非有機方式,為未來建立更強產品線的完美例子。這就是我在2018年及之後真正所指的內容。我目前不對有機占比或非有機占比做任何評論,但這個概念是:一旦我們把債務水位降到更可管理的程度,我們確實相信會有非有機成長的機會。不過很明顯,我們首先還有很多債務需要償還。我不想在轉型階段之前講得太超前。
- Analyst
- Analyst
Thank you very much.
非常感謝。
Operator
Operator
Prakash Gowd, CIBC.
Prakash Gowd,CIBC。
- Analyst
- Analyst
Joe, just a couple of questions.
Joe,我只有幾個問題。
First, on payers. I wonder if you could just maybe outline some of your discussions with payers and the outcomes there? Are you still seeing challenges from legacy pricing issues? Specifically, what steps are you taking to reverse any proposed formulary exclusions?
首先,關於付款方(payers)。我想請你概述一下你們與付款方的一些討論以及結果如何?你們是否仍然看到來自既有定價問題的挑戰?具體而言,為了扭轉任何擬議的處方集(formulary)排除,你們正在採取哪些步驟?
Secondly, on Xifaxan, you're probably in the midst of this strategy shift, moving from IBSD more to focusing on HE; and in Q1, you talked about implementation of educational programs and increasing the number of reps focusing on that. If you can update us on how that is progressing and when you think we can expect to see the full effect of these initiatives? Thanks very much.
第二,關於 Xifaxan,你們可能正處於這項策略轉變的過程中,從 IBSD 更轉向聚焦於 HE;而在第一季,你們談到推動教育計畫的落地,以及增加專注於該領域的業務代表人數。你能否更新一下目前進展如何,以及你認為何時我們可以看到這些措施的完整效果?非常感謝。
- CEO
- CEO
Sure. Let me start with the payers discussion -- yes, we have discussion with a number of payers. I will compliment the team that is here before I got here: Anne Whitaker and her team, Sandy, have done an outstanding job of improving our relationships with the payers. We feel good about where we are. There are still challenges, to be clear. I don't want to suggest for an instant that there's not challenges. There's still things we need to work on, but we like our position for 2016, as I mentioned. We have got a number of wins. I mentioned the Xifaxan win as certainly one example of a recent win that affects -- actually, it's two wins -- that affects combined 20 million lives, where we think that's a great opportunity to remove some of the step therapy hurdles that we have had.
當然。我先從付款方的討論開始——是的,我們與多家付款方都有在討論。我也要稱讚在我來之前就在這裡的團隊:Anne Whitaker 和她的團隊,以及 Sandy,在改善我們與付款方的關係方面做得非常出色。我們對目前的狀況感到樂觀。當然,仍然有挑戰。我不想讓人以為完全沒有挑戰;我們仍有一些事情需要努力,但如我所提到的,我們對 2016 年的布局感到滿意。我們已經取得了一些勝利。我提到的 Xifaxan 勝利就是近期的一個例子——其實是兩個勝利——合計影響 2,000 萬人的保障覆蓋,我們認為這是移除部分既有逐步治療(step therapy)門檻的絕佳機會。
That is what we are going to continue to work towards doing, just to make sure that our drugs are available for patients when they need them. It all goes back to what we are saying about our mission and trying to improve patients' lives with our healthcare products. That is really the focus we have taken and how we're going to continue to look to the future on trying to improve lives. There is no doubt, though, there is still going to still be challenges and we're going to work our way through them.
這正是我們將持續努力的方向,確保病患在需要時能取得我們的藥物。這一切都回到我們所說的使命:透過我們的醫療保健產品改善病患的生活。這就是我們採取的核心重點,也是我們未來持續前瞻、致力於改善生活的方式。不過毫無疑問,仍然會有挑戰,我們會一步步把它們解決。
On the questions of -- the next question you really was asked was about Xifaxan. We do believe hepatic encephalopathy is a very important opportunity for us. We wanted to make sure there were incremental resources put behind that opportunity, and Mark McKenna and his team have done that. We got, as I said, we have put an incremental 60-plus percentage more sales representatives behind hepatic encephalopathy. We think that's a place where we can make a very important contribution to a patient's life and reduce overall health care expenditures, because the facts are that those are very expensive patients. If we can reduce the need for rehospitalization or additional diagnostic work, that is important. That is what the team is working on.
至於下一個問題——你問的是 Xifaxan。我們確實相信肝性腦病變(hepatic encephalopathy)對我們而言是一個非常重要的機會。我們希望確保在這個機會上投入額外資源,而 Mark McKenna 和他的團隊已經做到了。如我所說,我們在肝性腦病變上投入了額外超過 60% 的業務代表人力。我們認為這是我們能對病患生活做出非常重要貢獻、並降低整體醫療支出的領域,因為事實上這些病患的醫療成本非常高。如果我們能降低再住院的需求或額外診斷檢查的需求,這就很重要。這正是團隊正在努力的方向。
Relative to when we're going to get there, in terms of hitting a peak performance, we think the peak performance of Xifaxan is certainly out many years. One of the things I talked about in the last call is that we think the potential opportunity for Xifaxan, if all patients for hepatic encephalopathy, for example, were treated, it would be a over a $5 billion opportunity. We are nowhere close to that. Let's be clear. But we do think there's certainly a significant upside from where we are today for Xifaxan. We have got a lot of years to still work on that and we are going to work very diligently on progressing our success with Xifaxan hepatic encephalopathy and IBSD, for that matter.
至於何時能達到高峰表現,我們認為 Xifaxan 的高峰表現肯定還在多年之後。我在上次電話會議提到的一點是:我們認為 Xifaxan 的潛在機會——例如若所有肝性腦病變病患都接受治療——將會是超過 50 億美元的機會。我們離那個目標還差得很遠,這點要說清楚。但我們確實認為,從目前的 Xifaxan 水準來看仍有顯著上行空間。我們還有很多年可以持續耕耘,我們也會非常努力推進 Xifaxan 在肝性腦病變以及 IBSD(就此而言)上的成功。
- Analyst
- Analyst
Can I ask a follow-up on the payer question? Just around your discussions with those payers, are the negotiations around you having to lower prices to maintain formulary status?
我可以就付款方的問題追問一下嗎?關於你們與那些付款方的討論,談判是否圍繞著你們必須降價才能維持處方集地位?
- CEO
- CEO
I would phrase it differently. I would phrase it, and what we have acknowledged earlier in this year, is that what we did is, we have looked at the amount of rebates and discounts that we provided to these payers to ensure that we got the appropriate access for our drugs. It is not so much reducing prices as much as it is looking at the rebate structure of what we're doing as a Company, is really been what has been gained the additional access for our products.
我會用不同的方式表述。我會說——而且我們今年稍早也已承認——我們所做的是檢視我們提供給這些付款方的回扣與折扣規模,以確保我們的藥物能取得適當的可近性(access)。與其說是降價,不如說是檢視公司在回扣結構上的作法;這才是真正為我們產品帶來額外可近性的原因。
- Analyst
- Analyst
Thank you, Joe.
謝謝你,Joe。
Operator
Operator
Murali Ganti, Citigroup.
Murali Ganti,花旗集團(Citigroup)。
- Analyst
- Analyst
My main debt-related questions have been answered, so maybe I'll ask a bigger-picture question here.
我主要與債務相關的問題已經得到解答,所以我想改問一個更宏觀的問題。
Operationally, are you now fully staffed at the senior management level? Do you have any more key hires you need to make to execute on your longer-term strategy, particularly with regard to the new segment structure you laid out?
在營運面上,你們現在在高階管理層是否已經完全補齊人力?為了執行你們的長期策略,特別是針對你們提出的新事業部門(segment)架構,你們是否還需要進行任何關鍵招募?
- CEO
- CEO
On the question of -- I feel very good about our team, but there are some additional hires that I do believe we need to make in the Company, yes. Look to us have more comment on that in the future. But I do feel we have got a good team, but there are still some additional areas that we want to strengthen at the Valeant organization. We will have more to say about that in the near future.
關於這個問題——我對我們的團隊感覺非常好,但我確實認為公司還需要再做一些額外招募,是的。未來請期待我們對此有更多說明。不過我確實覺得我們已經有一個很好的團隊,但在 Valeant 組織內仍有一些領域我們希望進一步強化。我們在不久的將來會有更多要說的。
- Analyst
- Analyst
Thank you.
謝謝。
Operator
Operator
Gregg Gilbert, Deutsche Bank.
Gregg Gilbert,德意志銀行(Deutsche Bank)。
- Analyst
- Analyst
One follow-up, Joe.
Joe,我有一個追問。
You mentioned one [thing] cushion on debt covenant. I'm sorry if I missed this, but can you describe the financial implications and the timeline to achieve that, at least generally, for us? Thanks.
你提到在債務契約(debt covenant)上有一個緩衝。我不確定我是否漏聽了,但你能否至少大致說明一下其財務影響以及達成的時間表?謝謝。
- CEO
- CEO
You're asking relative to the amendment, Gregg, that I mentioned?
Gregg,你是問我提到的那項修訂(amendment)嗎?
- Analyst
- Analyst
Yes.
是的。
- CEO
- CEO
I'll start, but Linda is going to give you the details on that, or give you some additional information on it. Obviously, we can't say anything because it's not final yet. But that is --
我先開頭,但 Linda 會提供你細節,或補充一些資訊。顯然,我們現在還不能說太多,因為尚未定案。不過那就是——
Gregg, I want to go back to my comments and what I was trying to say here. The issue that we face as a Company was that, since I've become the CEO of the Company, every single meeting, this question comes up. While it is a very important question, there's no doubt about it, I do also believe that it is something we can resolve. With the great work from Linda and her team, it is something we can get resolved relatively quickly, so Linda is going to take on this task of working through this amendment.
Gregg,我想回到我剛才的評論,以及我想表達的重點。我們公司面臨的問題是,自從我成為公司 CEO 以來,每一場會議都會出現這個問題。雖然這確實是非常重要的問題,毫無疑問,但我也相信這是我們可以解決的。在 Linda 和她團隊的出色工作下,這件事可以相對快速地解決,因此 Linda 會承擔起推進這項修訂、把它處理完成的任務。
Importantly, once -- Linda will go through the details of the financial side -- at least some of them; we can't give out too much yet -- but the important part for me, from a big picture point of view, is that once we get this behind us, we can go back to talking more about our products, how we plan to improve patients' lives, what our growth trajectory looks like, what the pipeline looks like, what we think is exciting about these new segment, in terms of what we think is durable growth for the future. That, we think is a lot more exciting than always talking about bank covenants. No disrespect to Linda and her role as the Treasurer.
更重要的是——Linda 會說明財務面的細節,至少其中一部分;我們現在還不能透露太多——但對我而言,從大局觀來看,重點在於一旦我們把這件事處理完,我們就能回到更多討論我們的產品、我們如何改善病患生活、我們的成長軌跡長什麼樣、研發管線長什麼樣、以及我們認為這些新事業部門有哪些令人振奮之處,從而帶來我們認為可持續的未來成長。我們認為這比一直談銀行契約要令人興奮得多。這並非對 Linda 及其作為財務主管(Treasurer)的角色有任何不敬。
But Linda, do you want to give any comments on the bank covenants and what you are doing?
不過 Linda,你要不要就銀行契約以及你正在做的事情補充幾句?
- Treasurer
- Treasurer
We haven't launched the amendment yet. We expect to launch later today. But as Joe mentioned, we will [define] the interest coverage, financial maintenance covenants, as well as a couple other small changes. This is all opportunistic and focused on giving us the flexibility to optimize our capital structure. While the interest coverage financial maintenance covenant is a big tight right now, with this additional cushion, we think we'll be very comfortable going forward. And to Joe's point, be able to focus on the strategy, the business, and talking about the business.
我們尚未正式啟動這項修訂。我們預期會在今天稍晚啟動。但如 Joe 所提到,我們將會[定義]利息保障倍數(interest coverage)、財務維持性契約(financial maintenance covenants),以及另外幾項小幅變更。這些都是把握時機、並聚焦於給我們彈性以最佳化資本結構。雖然目前利息保障倍數的財務維持性契約確實很緊,但有了這個額外緩衝後,我們認為未來會非常安心。也如 Joe 所說,我們就能把重心放回策略、業務本身,以及討論業務。
- Analyst
- Analyst
Thanks.
謝謝。
- CEO
- CEO
Thank you, Linda. Thank you, Gregg. We only have time for a couple more. We've gone a little bit even further -- we wanted to go further, but we've gone quite far, so let's maybe take another one or two questions, please.
謝謝你,Linda。謝謝你,Gregg。我們只剩下幾個問題的時間了。我們已經比原本預期的還要往後——我們本來想再多一些,但其實已經講得很久了,所以我們再請一到兩個問題,好嗎?
Operator
Operator
Doug Miehm, RBC Capital Markets.
Doug Miehm,RBC 資本市場(RBC Capital Markets)。
- Analyst
- Analyst
It's Joel on again. One quick follow-up on the access program amendment: we checked the pharmacy locator, and I'm wondering if you can outline the number of independent pharmacies you are working with? And again, how you expect that to drive volume growth going forward?
又是 Joel。我有一個關於可近性計畫(access program)修訂的快速追問:我們查看了藥局定位器(pharmacy locator),我想請問你能否概述一下你們正在合作的獨立藥局數量?另外,你們預期這將如何在未來推動銷量成長?
- CEO
- CEO
This is not going to be a scientific number, but the answer is all of them -- all of the independent pharmacies are eligible for our couponing program. Probably the best thing I can do -- that really is the magnitude of what it is. We have not specified any restrictions on independent pharmacies.
這不會是一個科學化的數字,但答案是全部——所有獨立藥局都符合我們的折價券計畫資格。也許我能做的最好的說法——這確實就是其規模之大。我們沒有對獨立藥局設定任何限制。
- Analyst
- Analyst
How does that compare to Walgreens locations? Is it double the number of Walgreens locations?
那和 Walgreens 的據點相比如何?是 Walgreens 據點數量的兩倍嗎?
- CEO
- CEO
I probably don't want to comment about the specifics on it, in terms of the actual numbers, but we just simply stated, as we have made it eligible for any independent pharmacy that they will have a couponing system for patients, that if a patient wants to go there, he or she can go there. I will say that we still believe the Walgreens program has preferable advantages for patients, but obviously individual patients should have the flexibility to make their decisions. But the Walgreens outlet is going to be a preferred outlet for all patients.
就實際數字的具體細節而言,我可能不想評論,但我們只是明確表示:我們已讓任何獨立藥局都具備資格,並且他們將為病患提供折價券系統;如果病患想去那裡,他或她就可以去。我會說,我們仍然相信 Walgreens 計畫對病患有較佳的優勢,但顯然個別病患應該有彈性自行做決定。不過,Walgreens 通路將會是所有病患的優先通路。
- Analyst
- Analyst
Okay. Just to follow up, how do you expect that to increase volume going forward for the derm portfolio recovery? Is there any quantification you can put to that?
好的。再追問一下,對於皮膚科產品組合的復甦,你預期這會如何在未來提高銷量?你能對此做任何量化嗎?
- CEO
- CEO
Probably, we saw, just really when the program was launched at the end of June, we did see some pickup in the prescriptions of our dermatology, but once again, it is probably too early to make any projections on exact numbers. But we are looking at trying to continue to increase this. We think it's especially important to get these programs in place. Because, as you know, people -- as many of the teenagers go back to school, that's an important time period for acne and other parts of dermatology franchise. So we think having these programs in place at the end of June and early August were very important to us, as we think about the future return to school type of prescriptions that we often see happen in dermatology.
大概是這樣:當該計畫在 6 月底推出時,我們確實看到皮膚科處方量有些回升,但再一次,現在要對精確數字做任何預測可能還太早。不過我們會持續努力提高。我們認為把這些計畫建立起來特別重要。因為如你所知,當許多青少年返校時,那是痤瘡以及皮膚科事業其他部分的一個重要時期。因此,我們認為在 6 月底與 8 月初把這些計畫到位對我們非常重要,因為我們在思考未來返校季時,皮膚科常會出現那類處方回升。
I don't want to give anything further beyond that other than it is very early in timing, but it's something that we're looking forward to and will continue to track very closely.
除了現在時點仍非常早之外,我不想再多說什麼,但這是我們期待的事情,也會持續非常密切地追蹤。
- Analyst
- Analyst
Okay, perfect. Thank you.
好的,完美。謝謝。
Operator
Operator
David Maris, Wells Fargo.
Wells Fargo 的 David Maris。
- Analyst
- Analyst
On the first-quarter slide, you had a slide on liquidity that, on the bottom said, based on guidance, we expect to remain in compliance with the credit agreement. That boxed shaded statement is not in the second-quarter slide deck. I just wanted to see if that was true or not, if based on your current guidance, you would expect to remain in compliance with the credit agreement as they stand now throughout 2016? Secondly--?
在第一季的投影片中,你們有一張關於流動性的投影片,底部寫著:根據財測指引,我們預期將持續符合信貸協議的規定。第二季的投影片簡報裡沒有那段框起來的陰影文字。我只是想確認那是否仍為真:也就是根據你們目前的指引,你們是否預期在 2016 年全年都能持續符合目前的信貸協議?第二個問題——?
- CEO
- CEO
The answer is yes, David. The answer is yes. That was one of the comments that was made. I made certainly, but Rob may have made mention, as well.
答案是肯定的,David。答案是肯定的。那是其中一項評論。我當然有提到,但 Rob 也可能有提及。
- Analyst
- Analyst
The other is, do you think -- to Gregg's question, the debt covenant amendments -- will they carry with them any cost? And does the guidance include that cost? And separately, does Nitropress and Isuprel generics, when you say they are in -- they are 6 to 12 months out, are they included in part in the current 2016 guidance?
另一個是,你認為——回到 Gregg 的問題,債務契約修訂——是否會伴隨任何成本?而指引是否已包含該成本?另外,當你說 Nitropress 和 Isuprel 的學名藥在——它們還有 6 到 12 個月,你們目前 2016 年的指引是否已部分納入?
- CEO
- CEO
First, Linda, on the question -- take the question on the debt covenants. We obviously cannot give that pricing information on things like that, David, because it obviously has not happened. We wanted to be transparent to let you know that we're going into the market with that. But until that happens, we cannot give exact numbers, but Linda has directionally thought about what that means to us. And Linda, anything else you can add to what I just stated?
首先,Linda,關於這個問題——先回答債務契約的問題。我們顯然無法提供那類事項的定價資訊,David,因為顯然尚未發生。我們希望透明地讓你知道我們正帶著這件事進入市場。但在事情發生之前,我們無法提供精確數字;不過 Linda 已從方向性角度思考這對我們意味著什麼。Linda,對我剛才所說的,你還能補充什麼嗎?
- Treasurer
- Treasurer
You've covered it, Joe.
你都說到了,Joe。
- Analyst
- Analyst
I just wondered, Joe, is that in the current guidance or not in the current guidance?
我只是想問,Joe,那是否已包含在目前的指引中,還是沒有包含在目前的指引中?
- CEO
- CEO
It is in the current guidance. That is correct. Yes, but we recognize that we do not have an exact number; we have a ballpark number or range of number. But just want to be clear that I don't have -- I can't know that until we actually get it completed.
它已包含在目前的指引中。沒錯。是的,但我們也承認我們沒有精確數字;我們只有一個大致的數字或區間。不過我想說清楚的是,在我們實際完成之前,我無法知道。
On the question on Nitropress and Isuprel -- as I said, I expect Nitropress to be first, Isuprel to be second. We think it's going to be, call it, in the next 6 to 12 months. Nitropress is included in 2016, at the latter part of 2016. Isuprel is in the 2017 time frame. That was the question you had, right David?
關於 Nitropress 和 Isuprel 的問題——如我所說,我預期 Nitropress 會先,Isuprel 會後。我們認為大概會在未來 6 到 12 個月內。Nitropress 已納入 2016 年,會在 2016 年後段。Isuprel 則是在 2017 年的時間範圍。這就是你的問題,對吧 David?
- Analyst
- Analyst
Yes. Lastly, you have on the slide deck a bridge slide that talks about the first half versus the second half. And something new in the slide deck is that it says that R&D timing will be a benefit. It's included in a few things, but a $0.38 benefit. Does that mean that R&D will be lower? It has to be, based on that slide -- lower in the second half?
是的。最後,你們在投影片簡報中有一張橋接圖,談到上半年與下半年的比較。投影片中新增的一點是,它寫到研發時點將帶來好處——它被包含在幾個項目裡,但有 0.38 美元的正面效益。這是否表示研發費用會更低?依那張投影片看——下半年會更低?
- CEO
- CEO
That's correct, David. We overspent R&D in the first half of the year, predominantly around the comments that Rob made specifically, to Brodalumab, and some of the new products that were coming through. It required us to overspend in the first half of the year versus our projections for the second half.
沒錯,David。我們在上半年研發支出超出預算,主要是圍繞 Rob 特別提到的 Brodalumab,以及一些正在推進的新產品。這使得我們上半年的研發支出相較於我們對下半年的預估更高。
- Analyst
- Analyst
Okay, great. Thank you.
好的,很好。謝謝。
- CEO
- CEO
Thank you. Operator, that concludes our call. Thank you very much, everyone, for your interest in Valeant. We will be out trying to answer any additional questions. If you have any additional questions, please get in touch with Valeant and we will be happy to try to provide additional information. Thank you very much for your participation today. Have a great day, everyone.
謝謝。接線員,我們的電話會議到此結束。非常感謝各位對 Valeant 的關注。我們會持續回覆任何額外問題。如果你有任何其他問題,請與 Valeant 聯繫,我們很樂意嘗試提供更多資訊。非常感謝各位今天的參與。祝大家有美好的一天。
Operator
Operator
This concludes today's conference call. You may now disconnect.
今天的電話會議到此結束。您現在可以掛線。